|
Previous: VANGUARD MORGAN GROWTH FUND INC, NSAR-A, EX-99, 2000-08-23 |
Next: NORTHERN STATES POWER CO /WI/, 8-K, 2000-08-23 |
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Filed by the Registrant [ ] | |
Filed by a Party other than the Registrant [X] | |
Check the appropriate box: |
[ ] Preliminary Proxy Statement [ ] | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
[ ] Definitive Proxy Statement | |
[X] Definitive Additional Materials |
[ ] | Soliciting Material Pursuant to § 240.14a-11(c) or § 240.14a-12 |
TENET HEALTHCARE CORPORATION
TENET SHAREHOLDER COMMITTEE, L.L.C.
Payment of Filing Fee (Check the appropriate box):
[X] | No fee required. | |
[ ] | $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6a-6(i)(2) or Item 22(a)(2) of Schedule 14A. | |
[ ] | Fee computed on table below per Exchange Act Rules 14a-6(i)(l) and 0-11. |
(1) Title of each class of securities to which transaction applies:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1) Amount previously paid:
Intended To Be Released To Security Holders
As of August 23, 2000
M. Lee Pearce, M.D.
1360 South Ocean Boulevard
PH 5
Pompano Beach, FL 33062
Direct: (954) 941-5570
August 22, 2000
Dear Tenet Shareholder:
The Tenet Shareholder Committee, L.L.C. (the Committee) nominated an opposition slate of candidates for election to the Board of Directors of Tenet Healthcare Corporation (the Company). Our reasons for doing so are described in the enclosures (Preliminary Proxy Statement, Time For A Change, the Tenet Healthcare Corporation Fact Book, and our letters to the Tenet Board).
In short, the Committee believes that significant changes in the Board of Directors of Tenet are necessary to revitalize the Company and improve and maximize shareholder value. Our materials show:
| The Companys poor financial performance over the past five years. |
| Tenet had the lowest return on assets in fiscal 1999 and is on track to repeat this feat in fiscal 2000 with its 2.2 percent return. | ||
| EBITDA margin declined steadily since peaking in fiscal 1996. The margin reached a new low of 17.0 percent in fiscal 2000. | ||
| Tenet has the highest debt-to-equity ratio of any of its competitors even after selling or closing 20 hospitals in fiscal 2000. | ||
| Tenet was below average on 20 of 21 financial measures when compared to its competitors and scored the worst performance on 11 of the measures, based on the latest comparable annual data. |
| The Companys exorbitant executive compensation and bloated management structure. |
| CEO Barbakow received $22.5 million in compensation in fiscal 1999, according to the Los Angeles Times. Over the past seven years, Barbakow was paid over $74 million, taking into account cash compensation and the value of stock options based on a share price of $30. |
| The Companys poor corporate governance practices. |
| Tenet twice disregarded strong majority shareholder votes to eliminate the staggered system of electing directors. |
The Committees candidates are committed to addressing these issues and are all well qualified to do so: |
| M. Lee Pearce, M.D. has extensive experience in the operation of hospitals and has been a director of publicly held hospital companies, including American Medical International (AMI) and OrNda Health Corporation, both of which Tenet acquired. | |
| Michael E. Gallagher provides advisory services to health care businesses, has been a director of a publicly held health care business, and held several positions with AMI, including Group Vice President Director of Corporate Development, Financial Planning and Controls. | |
| Ambassador Joseph M. Rodgers managed a successful business specializing in hospital construction before serving as the United States Ambassador to France. He is currently chairman of an investment firm and has considerable experience as a director of public companies. | |
| Claire S. Farley has a successful operating record in the petroleum industry and now heads a company offering medical diagnosis software and chronic condition management tools over the internet. |
The enclosed materials do not include a formal request for your proxy. On or about August 28, 2000, the Committee will send its Definitive Proxy Statement to all shareholders, and you may cast your vote for the Committees candidates at that time by executing the gold proxy card included in that package.
Until then, please review the enclosed materials and consider whether Tenets management, as represented by its candidates for director, has met your expectations as an investor. We think the answer should be no, and hope to have your support for the Committees candidates at the Annual Meeting of Shareholders in October.
The Committees candidates are not seeking to acquire control of the Board. Under the Companys By-Laws, the Board is divided into three classes of directors, with only one class elected each year on a rotating basis. No class is large enough to constitute a majority.
Sincerely, /S/ M. LEE PEARCE M. Lee Pearce, M.D., and the Tenet Shareholder Committee, L.L.C. |
Enclosures
-2-
Time for a Change
August 21, 2000
Tenet Shareholder Committee has nominated
4 directors to replace Tenets slate of
incumbent directors
| Why? |
| Poor Financial Performance | ||
| Exorbitant Executive Compensation and Bloated Management | ||
| Poor Corporate Governance Practices |
2
Did You Know?
Tenet has the worst ROA among its competitors in fiscal 1997, 1998 (excepting HCA, due to the Medicare fraud investigation), 1999, and is on track to repeat this feat in fiscal 2000.
1995 | 1996 | 1997 | 1998 | 1999 | 2000 | |||||
2.8% | 4.3% | (2.4)% | 2.1% | 1.9% | 2.2% |
SOURCE: Form 10-K for each respective company. Dividing net income by the average of beginning and ending assets. |
3
Did You Know?
Tenet has the worst ROE among its competitors in both fiscal 1997 & 1999 and without HCAs OIG payment, THC would repeat in F2000.
1995 | 1996 | 1997 | 1998 | 1999 | 2000 | |||||
10.0% | 15.1% | (8.3)% | 7.7% | 6.7% | 7.6% |
SOURCE: Form 10-K for each respective company. Dividing net income by the average of beginning and ending equity. |
4
Did You Know?
Tenet EBITDA margins peaked in fiscal 1996 ... and have declined steadily thereafter.
1996 | 1997 | 1998 | 1999 | 2000 | ||||
19.8% | 17.5% | 18.3% | 17.1% | 17.0% |
SOURCE: Form 10-K for each respective company. Dividing EBITDA by net revenue. |
5
Did You Know?
Tenet has consistently maintained the highest leverage among its competitors. From F1995 through F2000, Tenets Debt/Equity is the highest.
1995 | 1996 | 1997 | 1998 | 1999 | 2000 | |||||
1.79x | 1.23x | 1.57x | 1.64x | 1.66x | 1.40x |
SOURCE: Form 10-K for each respective company. Dividing short-term and long-term debt by equity. |
6
Did You Know?
Since fiscal 1995, Tenet has the highest level of debt to cash flow (Debt/EBITDA) among its competitors each and every year. Close to keeping record in 2000.
1995 | 1996 | 1997 | 1998 | 1999 | 2000 | |||||
5.71x | 2.96x | 3.31x | 3.23x | 3.46x | 2.93x |
SOURCE: Form 10-K for each respective company. Dividing short-term and long-term debt by EBITDA. |
7
Did You Know?
From fiscal 1997 1999, Tenets cost of
debt capital is the highest among its
competitors.
1997 | 1998 | 1999 | 2000 | |||||||
10.05% | 8.52% | 7.90% | 7.91% |
SOURCE: Form 10-K for each respective company. Dividing interest expense by the average of beginning and ending short-term and long-term debt. |
8
Did You Know?
Since fiscal 1994, Tenet has written off more than $2.15 billion after-tax, exceeding the total equity turned over to the management team in the beginning of fiscal 1994.
Source: Form 10-K. Sum of all restructuring and asset impairment changes, tax adjusted with a 40% tax rate, plus all after-tax discontinued operations and extraordinary item charges. |
9
Did You Know?
From fiscal 1995-2000, after Capital
Expenditures, Tenet produced NO CASH.
Tenet unfortunately, has not generated any
free cash flow over the last four years...
(WST 7/3/2000).
1995 | 1996 | 1997 | 1998 | 1999 | 2000 | |||||
(8.2)% | (3.1)% | 0.0% | (1.3)% | (0.1)% | 2.2% |
SOURCE: Form 10-K for each respective company. Dividing Cash Flow From Operations less Capital Expenditures by Net Revenue. |
10
Did You Know?
| A/R Days are UP 23.6 days since F1997. This increase required $738 Million in CASH to fund, negatively impacting EPS by $0.11 annually. |
1996 | 1997 | 1998 | 1999 | 2000 | ||||
55.0 | 56.5 | 64.3 | 77.8 | 80.1 |
SOURCE: Tenets Form 10-K for each year. Change in DSO in labeled year from three years earlier. Multiply $738 million by average cost of debt capital, with 40% tax rate and 314.9 MM fully diluted shares. |
11
Did You Know?
Tenet spends over $60 million annually for its legal counsel, hiring over 700 outside law firms? (House Counsel, Code Blue, GC Healthcare, May/June 2000).
12
Did You Know?
Tenet has admitted losing $100 million per year from its physician practices, an estimated $530 million to date. Another $500 million in write-offs makes managements mistake a $1 Billion error.
Source: Tenets investor presentation admits to $100 million operating loss. Our estimate of losses since end of fiscal 1993 is $530 million. Write-offs include $157 million from F97-F99 and $177 million in first 9 months of fiscal 2000 to cover about 40% of physician contracts. Total write-off to date is $334 million. Our $500 million estimate assumes a further write-off of $166 million for remaining 60% of physician practices. |
13
Below Competitors Average Performance in F1999
| Return on Assets* | |
| Return on Capital* | |
| Return on Equity* | |
| LTD / Equity* | |
| Total Debt / Equity* | |
| Total Debt / EBITDA* | |
| EBITDA / Interest* | |
| Average Cost of Debt* | |
| EBITDA Margin | |
| EBIT Margin | |
| Interest as % revenue* | |
| Pretax Margin* | |
| EBITDA / Share Growth | |
| Cash Flow Operations / Revenue* | |
| Cash Flow Operations Capital Expenditures/ Revenue | |
| Net A/R DSO | |
| Change in A/R DSO | |
| 3 Year Change in A/R DSO | |
| Revenue / Employee | |
| EBITDA / Employee |
* Lowest in F1999
14
Did You Know?
If we give 5 points to the best performer, and 1 point to the worst performer in each of 21 financial measurements, how do they rate?
Total | ||||||||
Average | Points | |||||||
4.24 | 89 | |||||||
3.57 | 75 | |||||||
3.29 | 69 | |||||||
2.10 | 44 | |||||||
1.81 | 38 |
Tenet has the worst performance in 11 of 21 measurements. Next worst is Quorum & HMA, scoring lowest just 3 times.
Source: See Tenet Fact Book for full details of each of the 21 financial measurements. All measurements for fiscal 1999 performance. |
15
Did You Know?
| According to the LA Times, CEO Barbakow was paid $22.5 million in 1999. | |
| At $30 per share, the company has paid Barbakow nearly $74 Million in 7 years. |
Source: Tenet proxy material of cash compensation and stock options. $74 million assumes that all options are cashed in at $30 per share. CEO has not exercised any options since assuming CEO post. |
16
Did You Know?
| Ex-COO Michael Focht retired on December 31, 1999. | |
| Yet Tenet still pays him $523,992 per year for consulting for 3 years. During this 3 years, he adds 3 years to his retirement vesting schedule and will receive annual compensation in the range of $486,000-$594,000 for a period of 10 years following his retirement. |
(Source: Fiscal 1999 and Fiscal 2000 Form 10-K, Exhibit 10-N) |
17
Did You Know?
Both Tenet and HCA have 1,450 employees at their corporate / operational / regional offices. Yet HCA owns 53% more beds than Tenet. On average, THC needs 11 corporate people / hospital. HCA provides better financial results with just 7.
Source: Tenet and HCA (Columbia/HCA)s Form-10K for total employees and Tenets F1999 10-K for corporate, operational and regional employees. HCAs corporate, operational and regional employees provided by HCA. Numbers of hospitals and licensed beds according to form 10-Ks for respective companies for fiscal 1999. |
18
Did You Know?
Both THC and HCA own comparably sized hospitals (237 beds vs. 221 beds / hospital). Yet THC needs 19% more employees (968/hospital) than HCA (812/hospital) to operate the hospitals.
Source: Tenet and HCA (Columbia/HCA)s Fiscal 1999 Form-10K for total employees. Numbers of hospitals and licensed beds according to Fiscal 1999 Form 10-Ks for respective companies. |
19
Did You Know?
At the last 2 annual shareholder meetings, shareholders have overwhelmingly voted to recommend that the Board eliminate the staggered system of electing directors: 62% and 71% respectively.
Source: Tenets Form 10-Q for November quarter of each fiscal year. |
20
Did You Know?
The Board ignored shareholders twice by maintaining staggered board elections.
21
| Board ignores shareholders staggered board recommendation | |
| Management is bloated and overpaid | |
| Management after 7 years has produced the worst operating results in the industry |
22
| Senior management should be comprised of hospital operators, rather than investment bankers. | |
| Headquarters should be moved out of Santa Barbara to Nashville and support staff downsized. | |
| The corporate air force should go. |
23
| Staggered board terms should be eliminated. | |
| The company should be operated for the benefit of shareholders rather than for entrenched management. |
24
Tenet Healthcare Corporation
Fact Book
Prepared by
Tenet Shareholder Committee, LLC.
August 21, 2000
All information in these slides was gathered from each companys Form 10-K filings, 10-Q filings and/or proxy material. Information for Tenet Healthcare has been updated for the companys fourth quarter fiscal 2000 earnings release. Estimates of earnings and cash flow for Tenets competitors are consistent with Wall Streets consensus earnings estimates as reported by firms such as First Call, I/B/E/S and Zacks Research. Estimates for all competitors have been updated for all earnings released prior to the date on the cover of this book.
Tenet Healthcare Corporation
Fact Book Table of Contents
Competitive Point Scores (THC vs. Competitors) | 5 | ||||||||
Comparing Tenet with its Competitors Return on Assets | 6 | ||||||||
Return on Capital | 7 | ||||||||
Return on Equity | 8 | ||||||||
Long Term Debt / Equity | 9 | ||||||||
Total Debt / Equity | 10 | ||||||||
Total Debt / EBITDA | 11 | ||||||||
EBITDA / Interest | 12 | ||||||||
Average Cost of Debt | 13 | ||||||||
EBITDA Margin | 14 | ||||||||
Depreciation & Amortization | 15 | ||||||||
EBIT Margin | 16 | ||||||||
Interest Expense | 17 | ||||||||
Pretax Margin | 18 | ||||||||
EBITDA / Share Growth | 19 | ||||||||
Cash Flow From Operations | 20 | ||||||||
Cash Flow After Capital Expenditures | 21 | ||||||||
Accounts Receivable DSO | 22 | ||||||||
Change in A/R DSO | 23 | ||||||||
3 Year Change in A/R DSO | 24 | ||||||||
Revenue Per Employee | 25 |
Tenet Healthcare Corporation
Fact Book Table of Contents
EBITDA Per Employee | 26 | ||||
THC vs. HCA Employment Levels | 27 | ||||
CEO Compensation | 28 | ||||
Accounts Receivable Analysis | 30 | ||||
Schedule of Non-Recurring Charges | 31 | ||||
Shareholder Votes Ignored by Board | 33 | ||||
Santa Barbara Headquarters | 35 | ||||
Tenet Healthcare Financials | 36 | ||||
HCA Financials | 41 | ||||
Universal Health Financials | 46 | ||||
Health Management Financials | 51 | ||||
Quorum Health Group Financials | 56 | ||||
Matrix of Financial Indicators | 61 |
Competitive Point Scores
(5 = Best to 1 = Worst)
THC | HCA | UHS | HMA | QHGI | ||||||||||||||||
Return on Assets | 1.00 | 3.00 | 4.00 | 5.00 | 2.00 | |||||||||||||||
Return on Capital | 1.00 | 3.00 | 4.00 | 5.00 | 2.00 | |||||||||||||||
Return on Equity | 1.00 | 3.00 | 4.00 | 5.00 | 2.00 | |||||||||||||||
LTD : Equity | 1.00 | 3.00 | 4.00 | 5.00 | 2.00 | |||||||||||||||
Total Debt : Equity | 1.00 | 3.00 | 4.00 | 5.00 | 2.00 | |||||||||||||||
Total Debt : EBITDA | 1.00 | 3.00 | 4.00 | 5.00 | 2.00 | |||||||||||||||
EBITDA : Interest | 1.00 | 3.00 | 4.00 | 5.00 | 2.00 | |||||||||||||||
Average Cost of Debt | 1.00 | 3.00 | 4.00 | 5.00 | 2.00 | |||||||||||||||
EBITDA Margin | 3.00 | 4.00 | 1.00 | 5.00 | 2.00 | |||||||||||||||
D&A % of Revenue | 4.00 | 1.00 | 3.00 | 5.00 | 2.00 | |||||||||||||||
EBIT Margin | 4.00 | 3.00 | 1.00 | 5.00 | 2.00 | |||||||||||||||
Interest % of Revenue | 1.00 | 3.00 | 4.00 | 5.00 | 2.00 | |||||||||||||||
Pretax Margin | 1.00 | 4.00 | 3.00 | 5.00 | 2.00 | |||||||||||||||
EBITDA / Share Growth | 2.00 | 4.00 | 3.00 | 5.00 | 1.00 | |||||||||||||||
Cash Flow Operations : Revenue | 1.00 | 2.00 | 4.00 | 5.00 | 3.00 | |||||||||||||||
Cash Flow Operations Cap Ex : Revenue | 2.00 | 1.00 | 5.00 | 4.00 | 3.00 | |||||||||||||||
Net A/R DSO | 2.00 | 5.00 | 4.00 | 1.00 | 3.00 | |||||||||||||||
Change in A/R DSO | 2.00 | 5.00 | 4.00 | 1.00 | 3.00 | |||||||||||||||
Three Year Change in A/R DSO | 2.00 | 5.00 | 4.00 | 1.00 | 3.00 | |||||||||||||||
Revenue : Employee | 3.00 | 4.00 | 5.00 | 2.00 | 1.00 | |||||||||||||||
EBITDA : Employee | 3.00 | 4.00 | 2.00 | 5.00 | 1.00 | |||||||||||||||
Total Points | 38.00 | 69.00 | 75.00 | 89.00 | 44.00 | |||||||||||||||
Average | 1.81 | 3.29 | 3.57 | 4.24 | 2.10 | |||||||||||||||
# Best | | 3.00 | 2.00 | 16.00 | | |||||||||||||||
# Worst | 11.00 | 2.00 | 2.00 | 3.00 | 3.00 |
Page 5
Return on Assets
Net Income / Assets
Below Competitors Average Every Year F95 00E
Lowest F95, F97, F99 & F00E
SOURCE: Form 10-K for each respective company. Dividing net income by the average of beginning and ending assets. |
Page 6
Return on Capital
Net Income / Debt + Equity
Worst Performer F97, 99 & 00E
SOURCE: Form 10-K for each respective company. Dividing net income by the average of beginning and ending short term debt, long term debt and equity. |
Page 7
Return on Equity
Net Income / Equity
Below Competitors Average Every Year F95 00E
Worst Performer F97, & 99
SOURCE: Form 10-K for each respective company. Dividing net income by the average of beginning and ending equity. |
Page 8
Long Term Debt / Equity
Highest Leveraged Company Every Year
SOURCE: Form 10-K for each respective company. Dividing long-term debt by equity. |
Page 9
Total Debt / Equity
Highest Leveraged Company Every Year
SOURCE: Form 10-K for each respective company. Dividing short-term and long-term debt by equity. |
Page 10
Total Debt / EBITDA
Perennial Leverage Leader
Quorums awful performance wins F2000E
SOURCE: Form 10-K for each respective company. Dividing short-term and long-term debt by EBITDA. |
Page 11
EBITDA / Interest
Worst Interest Coverage Every Year
SOURCE: Form 10-K for each respective company. Dividing EBITDA by interest expense. |
Page 12
Average Cost of Debt
Highest Cost of Debt Capital F1997-1999
SOURCE: Form 10-K for each respective company. Dividing interest expense by the average of beginning and ending short-term and long-term debt. |
Page 13
EBITDA Margin
Margins Peaked in F1996
HCA beats Tenet before & after OIG impact
SOURCE: Form 10-K for each respective company. Dividing EBITDA by net revenue. |
Page 14
Depreciation & Amortization
% of Revenue
Massive Write-Offs Dropped Expense 110 BP Since 1996
150 BP Difference Between THC & HCA
SOURCE: Form 10-K for each respective company. Dividing depreciation and amortization by net revenue. |
Page 15
EBIT Margin
HCA Beating THC Both Before &
After OIG
Investigation Impact
SOURCE: Form 10-K for each respective company. Dividing EBIT by net revenue. |
Page 16
Interest Expense
Highest Interest Burden in the Industry Every Year
SOURCE: Form 10-K for each respective company. Dividing interest expense by net revenue. |
Page 17
Pretax Margin
Below Competitors Average Every Year F97 00E
Worst Margin 1999
SOURCE: Form 10-K for each respective company. Dividing pre-tax income by net revenue. |
Page 18
EBITDA / Share Growth
Outside of Merger impacts, very little growth.
Competitors Growing 3-7x Faster
SOURCE: Form 10-K for each respective company. Dividing EBITDA / Share in stated year by EBITDA / Share in prior year. |
Page 19
Cash Flow From Operations
% of Revenue
Worst Performer Every Year
SOURCE: Form 10-K for each respective company. Dividing Cash Flow From Operations by Net Revenue. |
Page 20
Cash Flow After Capital
Expenditures
% of Revenue
Using (NOT Generating) Cash from 1995 2000E
No Demonstrated Ability to Amortize Debt
SOURCE: Form 10-K for each respective company. Dividing Cash Flow From Operations less Capital Expenditures by Net Revenue. |
Page 21
Accounts Receivable
Days Outstanding
Higher Than Competitors Average Every Year F95 00E
Worst Performance in F2000
SOURCE: Form 10-K for each respective company. Dividing Net Accounts Receivable by Net Revenues divided by 365. |
Page 22
Change in A/R DSO
Higher Than Competitors Average Every Year F97 00E
SOURCE: Form 10-K for each respective company. Change in DSO in labeled year from the prior year. |
Page 23
Change in DSO
Higher Than Competitors Average F97, 99 & 00E
SOURCE: Form 10-K for each respective company. Change in DSO in labeled year from three years earlier. |
Page 24
Revenue Per Employee
HCA Outperforming THC 1999. Fiscal 2000 Spike Caused by
Sale / Closure of 20 Hospitals With Partial Year Revenue
SOURCE: Form 10-K for each respective company. Annual net revenues divided by number of employees at year-end. |
Page 25
EBITDA Per Employee
(in thousands)
HCA Outperforming THC 1999. Fiscal 2000 Spike Caused by
Sale / Closure of 20 Hospitals With Partial Year Revenue
SOURCE: Form 10-K for each respective company. EBITDA divided by employees at year-end. |
Page 26
Tenet vs. HCA Employment Levels
Source: THC Form 10-K, HCA Form 10-K & Management Interview
THC | HCA | Difference | ||||||||||
Hospitals at FY1999 year-end | 130 | 207 | -37 | % | ||||||||
Licensed beds at year-end | 30,791 | 45,663 | -33 | % | ||||||||
Average licensed beds / hospital | 237 | 221 | 7 | % | ||||||||
Total Employees | 125,950 | 168,000 | -25 | % | ||||||||
Employees / Hospital | 968.85 | 811.59 | 19 | % | ||||||||
Employees / Licensed Bed | 4.09 | 3.68 | 11 | % | ||||||||
Corporate / Operational / Regional Employees (Support Employees) | 1,450 | 1,450 | 0 | % | ||||||||
Support Employees / Hospital | 11.15 | 7.00 | 59 | % | ||||||||
Support Employees / Licensed Bed | 0.05 | 0.03 | 48 | % |
Page 27
Tenet Healthcare Corporation
CEO Compensation
Proxy | Barbakow | Barbakow | Barbakow | Option | Option | Vesting | Options | Options | ||||||||||||||||||||||||||
Year | Shares | Options | Options | Price | Expires | Exercisable | Unexercisable | |||||||||||||||||||||||||||
Owned | Exercised | Added | Added | |||||||||||||||||||||||||||||||
1994 | 19,100 | | 2,000,000 | $ | 9.500 | 6/1/03 | 1/3 annually | | 2,098,000 | |||||||||||||||||||||||||
98,000 | $ | 11.625 | 12/1/03 | 5/31/96 | ||||||||||||||||||||||||||||||
1995 | 19,400 | | 500,000 | $ | 13.875 | 1/22/05 | 1/3 annually | 666,666 | 1,931,334 | |||||||||||||||||||||||||
1996 | 19,400 | | | 1,597,999 | 1,000,001 | |||||||||||||||||||||||||||||
1997 | 22,450 | | 900,000 | $ | 21.625 | 5/31/06 | 2/3 5/31/98 | 2,431,333 | 1,066,667 | |||||||||||||||||||||||||
Includes 3,050 held by minor sons. | 1/3 5/31/99 | |||||||||||||||||||||||||||||||||
1998 | 52,450 | | | 2,598,000 | 900,000 | |||||||||||||||||||||||||||||
Includes 3,050 held by minor sons. | ||||||||||||||||||||||||||||||||||
1999 | 164,550 | | 1,500,000 | $ | 30.438 | 6/23/08 | 2/3 6/24/00 | 3,198,000 | 1,800,000 | |||||||||||||||||||||||||
Includes 11,350 held by minor sons. | ||||||||||||||||||||||||||||||||||
2000 | 1,152,013 | | | 3,498,000 | 1,500,000 | |||||||||||||||||||||||||||||
Includes 12,180 held by minor sons. | ||||||||||||||||||||||||||||||||||
Option Recap | $ | 26.00 | $ | 27.00 | $ | 28.00 | $ | 30.00 | $ | 32.00 | ||||||||||||||||||||||||
2,000,000 | $ | 9.50 | 33,000,000 | 35,000,000 | 37,000,000 | 41,000,000 | 45,000,000 | |||||||||||||||||||||||||||
98,000 | $ | 11.63 | 1,408,750 | 1,506,750 | 1,604,750 | 1,800,750 | 1,996,750 | |||||||||||||||||||||||||||
500,000 | $ | 13.88 | 6,062,500 | 6,562,500 | 7,062,500 | 8,062,500 | 9,062,500 | |||||||||||||||||||||||||||
900,000 | $ | 21.63 | 3,937,500 | 4,837,500 | 5,737,500 | 7,537,500 | 9,337,500 | |||||||||||||||||||||||||||
1,500,000 | $ | 30.44 | 2,343,000 | |||||||||||||||||||||||||||||||
$ | 44,408,750 | $ | 47,906,750 | $ | 51,404,750 | $ | 58,400,750 | $ | 67,739,750 | |||||||||||||||||||||||||
Cash Comp | $ | 15,556,506 | $ | 15,556,506 | $ | 15,556,506 | $ | 15,556,506 | $ | 15,556,506 | ||||||||||||||||||||||||
7 Yr Comp | $ | 59,965,256 | $ | 63,463,256 | $ | 66,961,256 | $ | 73,957,256 | $ | 83,296,256 |
Page 28
Tenet Healthcare Corporation
CEO Compensation
Salary | Bonus | Other | Total | All | Cost | |||||||||||||||||||
Cash | Other | for CEO | ||||||||||||||||||||||
Comp | Comp | Personal | ||||||||||||||||||||||
1994 | $ | 850,000 | $ | 892,500 | $ | 110,000 | $ | 1,852,500 | $ | 3,647 | $ | 43,700 | ||||||||||||
1995 | $ | 900,000 | $ | 574,560 | $ | 125,813 | $ | 1,600,373 | $ | 43,554 | $ | 36,535 | ||||||||||||
1996 | $ | 945,000 | $ | 1,165,707 | $ | 61,933 | $ | 2,172,640 | $ | 58,747 | $ | 55,710 | ||||||||||||
1997 | $ | 992,250 | $ | 1,262,947 | $ | 64,950 | $ | 2,320,147 | $ | 66,557 | $ | 57,982 | ||||||||||||
1998 | $ | 1,091,475 | $ | 1,627,190 | $ | 78,420 | $ | 2,797,085 | $ | 77,404 | $ | 42,884 | ||||||||||||
1999 | $ | 1,091,475 | $ | 671,257 | $ | 59,318 | $ | 1,822,050 | $ | 89,008 | $ | 36,421 | ||||||||||||
2000 | $ | 1,124,000 | $ | 1,802,115 | $ | 65,596 | $ | 2,991,711 | $ | 64,471 | $ | 47,290 |
Page 29
Tenet Healthcare Corporation
Accounts Receivable Analysis
Year | Revenue | A/R | DSO | |||||||||
($ Millions) | ($ Millions) | |||||||||||
1994 | 2,967 | 385 | 47.4 | |||||||||
1995 | 3,318 | 565 | 62.2 | |||||||||
1996 | 5,559 | 838 | 55.0 | |||||||||
1997 | 8,691 | 1,346 | 56.5 | |||||||||
1998 | 9,895 | 1,742 | 64.3 | |||||||||
1999 | 10,880 | 2,318 | 77.8 | |||||||||
2000 | 11,414 | 2,506 | 80.1 |
Change from Base Year to Q3-F00
F2000 | DSO | Change | ||||||||||
1996 | 80.1 | 55.0 | 25.1 | |||||||||
1997 | 80.1 | 56.5 | 23.6 | |||||||||
1998 | 80.1 | 64.3 | 15.9 | |||||||||
1999 | 80.1 | 77.8 | 2.4 |
Cash Required to Fund A/R Increase from Base Year
Using F2000 Revenues of $11.414 Billion
($ in Millions)
1996 | $ | 785.4 | ||
1997 | $ | 738.2 | ||
1998 | $ | 496.6 | ||
1999 | $ | 74.2 |
Page 30
Tenet Healthcare
Schedule of Non-Recurring Charges
($ Millions) | Restructuring | Asset | Discontinued | Extraordinary | ||||||||||||
Charges | Impairment | Operations | Charge | |||||||||||||
Pre-Tax | Pre-Tax | After-Tax | After-Tax | |||||||||||||
Fiscal 1994 | ||||||||||||||||
Sell Santa Monica headquarters building | (77 | ) | ||||||||||||||
Discontinued Psychiatric Operations | (701 | ) | ||||||||||||||
Fiscal 1995 | ||||||||||||||||
Move Operational Offices to Dallas and AMI severance | (37 | ) | ||||||||||||||
Discontinued Psychiatric Operations | (9 | ) | ||||||||||||||
Early Retirement of Debt | (20 | ) | ||||||||||||||
Fiscal 1996 | ||||||||||||||||
Impairment losses on asset values | (86 | ) | ||||||||||||||
Discontinued Psychiatric Operations | (25 | ) | ||||||||||||||
Early Retirement of Debt | (23 | ) | ||||||||||||||
Fiscal 1997 | ||||||||||||||||
OrNda Merger Charge | (188 | ) | ||||||||||||||
Asset impairment of THC and OrNda Hospitals | (353 | ) | ||||||||||||||
Goodwill write-off of physician practices | (60 | ) | ||||||||||||||
Restructuring physician practices | (18 | ) | ||||||||||||||
Discontinued Psychiatric Operations | (134 | ) | ||||||||||||||
Early Retirement of Debt | (47 | ) | ||||||||||||||
Prior Period Adjustments (F94/95/96) | (10 | ) | ||||||||||||||
Fiscal 1998 | ||||||||||||||||
Plan to sell or close hospitals | (160 | ) |
Page 31
Tenet Healthcare
Schedule of Non-Recurring Charges
($ Millions) | Restructuring | Asset | Discontinued | Extraordinary | ||||||||||||
Charges | Impairment | Operations | Charge | |||||||||||||
Pre-Tax | Pre-Tax | After-Tax | After-Tax | |||||||||||||
Write-off of goodwill for physician practice | (41 | ) | ||||||||||||||
Impairment of hospital assets | (20 | ) | ||||||||||||||
Early Retirement of Debt | (117 | ) | ||||||||||||||
Fiscal 1999 | ||||||||||||||||
Plan to sell or close hospitals | (277 | ) | ||||||||||||||
Impairment of physician practice assets | (38 | ) | ||||||||||||||
Cost reduction plans | (48 | ) | ||||||||||||||
Fiscal 2000 | ||||||||||||||||
Impairment of physician practice assets | (177 | ) | ||||||||||||||
Plan to sell or close hospitals | (178 | ) | ||||||||||||||
Discontinued Psychiatric Operations | (19 | ) | ||||||||||||||
Fiscal 1994 - 2000 Totals | (378 | ) | (1,390 | ) | (888 | ) | (207 | ) | ||||||||
Taxes @ 40% | 151 | 556 | ||||||||||||||
After-Tax Charges | (227 | ) | (834 | ) | (888 | ) | (207 | ) | ||||||||
TOTAL After-Tax Charges / Write-Offs | (2,156 | ) |
Page 32
Tenet Healthcare Corporation
Shareholder Votes Ignored by Board
Vote at the 1999 Annual Shareholder Meeting
Declassification of the Companys Board of Directors
Result: Board Ignored Shareholders
Votes | % Voting | % Total | ||||||||||
For Declassification | 163,346,307 | 62.2 | % | 61.9 | % | |||||||
Against Declassification | 99,455,258 | 37.8 | % | 37.7 | % | |||||||
Abstaining | 1,031,322 | 0.4 | % | |||||||||
263,832,887 | 100.0 | % | 100.0 | % |
Eliminate Shareholders Rights Plan
Result: Board Redeemed Rights
Votes | % Voting | % Total | ||||||||||
For Elimination | 200,284,495 | 76.3 | % | 75.9 | % | |||||||
Against Elimination | 62,332,407 | 23.7 | % | 23.6 | % | |||||||
Abstaining | 1,215,985 | 0.5 | % | |||||||||
263,832,887 | 100.0 | % | 100.0 | % | ||||||||
Percentage of Votes AGAINST Incumbent Directors | 8.78 | % |
Page 33
Tenet Healthcare Corporation
Shareholder Votes Ignored by Board
Vote at the 1998 Annual Shareholder Meeting
Declassification of the Companys Board of Directors
Result: Board Ignored Shareholders
Votes | % Voting | % Total | ||||||||||
For Declassification | 187,596,345 | 72.9 | % | 71.1 | % | |||||||
Against Declassification | 69,771,022 | 27.1 | % | 26.4 | % | |||||||
Abstaining | 1,481,280 | 0.6 | % | |||||||||
258,848,647 | 100.0 | % | 98.1 | % | ||||||||
Percentage of Votes AGAINST Incumbent Directors | 0.77 | % |
Page 34
WHY SANTA BARBARA?
Answer: CEO Barbakow Wants To Live There
Mr. Mackey Had To Relocate to Santa Barbara
Cost? | $ | 557,485 |
Mr. Fetter Had To Relocate to Santa Barbara
Cost? | $ | 645,110 |
Mr. Brown Had To Relocate to Santa Barbara
Cost? | $ | 30,289 |
Mr. Mathiasen Had To Relocate to Santa Barbara
Cost? | $ | 61,331 |
Disconnect Between Corporate and Hospital Operations
Encourages Corporate Air Force
Encourages Culture of Corporate Waste; Focus on resort lifestyle rather than operating hospitals
Page 35
Tenet Healthcare Corporation
Income Statement | ||||||||||||||||||||||||||||||||
Years as Originally Reported | ||||||||||||||||||||||||||||||||
($ in millions, except per share) | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | ||||||||||||||||||||||||
Net operating revenues | 3,191 | 2,967 | 3,318 | 5,559 | 8,691 | 9,895 | 10,880 | 11,414 | ||||||||||||||||||||||||
Salaries and benefits | 1,367 | 2,194 | 3,595 | 4,052 | 4,412 | 4,508 | ||||||||||||||||||||||||||
Supplies | 432 | 764 | 1,197 | 1,375 | 1,525 | 1,595 | ||||||||||||||||||||||||||
Provision for doubtful accounts | 137 | 290 | 498 | 588 | 743 | 851 | ||||||||||||||||||||||||||
Other operating expenses | 2,680 | 2,415 | 759 | 1,212 | 1,878 | 2,071 | 2,342 | 2,525 | ||||||||||||||||||||||||
Operating Expenses | 2,680 | 2,415 | 2,695 | 4,460 | 7,167 | 8,086 | 9,022 | 9,479 | ||||||||||||||||||||||||
EBITDA | 511 | 552 | 623 | 1,099 | 1,524 | 1,809 | 1,858 | 1,935 | ||||||||||||||||||||||||
Depreciation | 160 | 161 | 164 | 240 | 335 | 347 | 421 | 411 | ||||||||||||||||||||||||
Amortization | 31 | 81 | 108 | 113 | 135 | 122 | ||||||||||||||||||||||||||
EBIT | 351 | 391 | 428 | 778 | 1,081 | 1,349 | 1,302 | 1,402 | ||||||||||||||||||||||||
Net Interest expense (income) | 75 | 70 | 138 | 312 | 417 | 464 | 485 | 479 | ||||||||||||||||||||||||
Operating Income | 276 | 321 | 290 | 466 | 664 | 885 | 817 | 923 | ||||||||||||||||||||||||
Investment earnings | 21 | 28 | 27 | 22 | 26 | 22 | 27 | 22 | ||||||||||||||||||||||||
Impairment charges | (77 | ) | (37 | ) | (86 | ) | (619 | ) | (221 | ) | (363 | ) | (355 | ) | ||||||||||||||||||
Gain (Loss) on Asset Sales | 122 | 88 | 30 | 346 | (18 | ) | (17 | ) | 49 | |||||||||||||||||||||||
Equity in unconsolidated sub | 28 | 20 | 1 | |||||||||||||||||||||||||||||
Minority interests consol sub | (9 | ) | (22 | ) | (27 | ) | (22 | ) | (7 | ) | (21 | ) | ||||||||||||||||||||
Pretax income | 419 | 360 | 329 | 746 | 26 | 647 | 474 | 618 | ||||||||||||||||||||||||
Income taxes | 155 | 144 | 135 | 348 | 89 | 269 | 225 | 278 | ||||||||||||||||||||||||
Net income - Continuing Operations | 264 | 216 | 194 | 398 | (63 | ) | 378 | 249 | 340 | |||||||||||||||||||||||
Discontinued operations (net of tax) | (104 | ) | (701 | ) | (9 | ) | (25 | ) | (134 | ) | (19 | ) | ||||||||||||||||||||
Extraordinary Item (net of tax) | 60 | (20 | ) | (23 | ) | (47 | ) | (117 | ) | (19 | ) | |||||||||||||||||||||
Net Income | 160 | (425 | ) | 165 | 350 | (244 | ) | 261 | 249 | 302 | ||||||||||||||||||||||
EPS Operations | $ | 1.01 | $ | 0.93 | $ | 1.08 | $ | 1.34 | $ | 1.43 | $ | 1.72 | $ | 1.64 | $ | 1.81 | ||||||||||||||||
Impairment & Asset Sale Impact | $ | 0.48 | $ | 0.29 | $ | (0.02 | ) | $ | 0.51 | $ | (1.64 | ) | $ | (0.50 | ) | $ | (0.85 | ) | $ | (0.84 | ) | |||||||||||
EPS, After Impairment | $ | 1.49 | $ | 1.23 | $ | 1.06 | $ | 1.86 | $ | (0.21 | ) | $ | 1.21 | $ | 0.79 | $ | 0.97 | |||||||||||||||
EPS, After Discontinued & Extraordinary Items | $ | 0.91 | $ | (2.54 | ) | $ | 0.91 | $ | 1.63 | $ | (0.80 | ) | $ | 0.84 | $ | 0.79 | $ | 0.96 | ||||||||||||||
Pretax - Operations | 297 | 349 | 336 | 486 | 663 | 885 | 837 | 924 | ||||||||||||||||||||||||
Taxes - Operations | 119 | 140 | 138 | 199 | 272 | 350 | 322 | 360 | ||||||||||||||||||||||||
Net Income - Operations | 178 | 209 | 198 | 287 | 391 | 535 | 515 | 564 | ||||||||||||||||||||||||
EPS - Fully Diluted - Operations | $ | 1.01 | $ | 1.19 | $ | 1.08 | $ | 1.34 | $ | 1.29 | $ | 1.72 | $ | 1.64 | $ | 1.79 |
Page 36
1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | |||||||||||||||||||||||||
Primary Shares Outstanding | 166.1 | 167.0 | 176.8 | 209.5 | 303.9 | 306.3 | 310.1 | 312.0 | ||||||||||||||||||||||||
Fully Diluted Shares Outstanding | 180.5 | 181.1 | 190.1 | 216.7 | 304.2 | 312.1 | 313.4 | 314.9 | ||||||||||||||||||||||||
Expense Ratios: | ||||||||||||||||||||||||||||||||
Salaries and benefits | 41.2 | % | 39.5 | % | 41.4 | % | 40.9 | % | 40.6 | % | 39.5 | % | ||||||||||||||||||||
Supplies | 13.0 | % | 13.7 | % | 13.8 | % | 13.9 | % | 14.0 | % | 14.0 | % | ||||||||||||||||||||
Provision for doubtful accounts | 4.1 | % | 5.2 | % | 5.7 | % | 5.9 | % | 6.8 | % | 7.5 | % | ||||||||||||||||||||
Other operating expenses | 22.9 | % | 21.8 | % | 21.6 | % | 20.9 | % | 21.5 | % | 22.1 | % | ||||||||||||||||||||
Operating Expenses | 81.2 | % | 80.2 | % | 82.5 | % | 81.7 | % | 82.9 | % | 83.0 | % | ||||||||||||||||||||
EBITDA Margin | 16.0 | % | 18.6 | % | 18.8 | % | 19.8 | % | 17.5 | % | 18.3 | % | 17.1 | % | 17.0 | % | ||||||||||||||||
Depreciation | 5.0 | % | 5.4 | % | 4.9 | % | 4.3 | % | 3.9 | % | 3.5 | % | 3.9 | % | 3.6 | % | ||||||||||||||||
Amortization | 0.9 | % | 1.5 | % | 1.2 | % | 1.1 | % | 1.2 | % | 1.1 | % | ||||||||||||||||||||
EBIT Margin | 11.0 | % | 13.2 | % | 12.9 | % | 14.0 | % | 12.4 | % | 13.6 | % | 12.0 | % | 12.3 | % | ||||||||||||||||
Interest Expense | 2.4 | % | 2.4 | % | 4.2 | % | 5.6 | % | 4.8 | % | 4.7 | % | 4.5 | % | 4.2 | % | ||||||||||||||||
Operating Margin | 8.6 | % | 10.8 | % | 8.7 | % | 8.4 | % | 7.6 | % | 8.9 | % | 7.5 | % | 8.1 | % | ||||||||||||||||
Pretax Margin | 13.1 | % | 12.1 | % | 9.9 | % | 13.4 | % | 0.3 | % | 6.5 | % | 4.4 | % | 5.4 | % | ||||||||||||||||
Tax Rate | 37.0 | % | 40.0 | % | 41.0 | % | 46.6 | % | 342.3 | % | 41.6 | % | 47.5 | % | 45.0 | % |
Page 37
Tenet Healthcare Corporation
Cash Flow Statement
($ in millions, except per share) | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | |||||||||||||||||||||||||
Cash Flow from Operations | |||||||||||||||||||||||||||||||||
Net income | (425 | ) | 165 | 350 | (244 | ) | 261 | 249 | 302 | ||||||||||||||||||||||||
Depreciation & amortization | 198 | 195 | 321 | 443 | 460 | 556 | 533 | ||||||||||||||||||||||||||
Doubtful accounts | 494 | 588 | 743 | 851 | |||||||||||||||||||||||||||||
Deferred taxes | (253 | ) | 95 | 243 | (200 | ) | 131 | 101 | 2 | ||||||||||||||||||||||||
Discontinued operations | 856 | (356 | ) | 53 | 955 | (47 | ) | 288 | (91 | ) | |||||||||||||||||||||||
Net loss (gain) on divestitures | (88 | ) | (30 | ) | (346 | ) | 18 | 17 | 358 | ||||||||||||||||||||||||
Working capital | (119 | ) | (70 | ) | (438 | ) | (1,135 | ) | (1,028 | ) | (1,372 | ) | (1,086 | ) | |||||||||||||||||||
Change in short/current debt | |||||||||||||||||||||||||||||||||
Other | (22 | ) | (6 | ) | 12 | 73 | 21 | 17 | |||||||||||||||||||||||||
Cash provided from Operations | 147 | (7 | ) | 195 | 404 | 403 | 582 | 869 | |||||||||||||||||||||||||
Cash Flow from Investing | |||||||||||||||||||||||||||||||||
Proceeds from asset sales | 569 | 172 | 548 | 50 | 170 | 72 | 764 | ||||||||||||||||||||||||||
Hospital acquisitions | (5 | ) | (1,429 | ) | (410 | ) | (787 | ) | (679 | ) | (646 | ) | (38 | ) | |||||||||||||||||||
Capital expenditures | (185 | ) | (264 | ) | (370 | ) | (406 | ) | (534 | ) | (592 | ) | (619 | ) | |||||||||||||||||||
Increase in intangible assets | (24 | ) | |||||||||||||||||||||||||||||||
Collection of notes receivable | 100 | ||||||||||||||||||||||||||||||||
Other investing activity | (69 | ) | 8 | (36 | ) | 18 | (40 | ) | 19 | (143 | ) | ||||||||||||||||||||||
Cash provided from investing | 386 | (1,513 | ) | (268 | ) | (1,125 | ) | (1,083 | ) | (1,147 | ) | (36 | ) | ||||||||||||||||||||
Cash Flow From Financing | |||||||||||||||||||||||||||||||||
Bank borrowings | (337 | ) | 1,354 | (226 | ) | 605 | 587 | 549 | (787 | ) | |||||||||||||||||||||||
Proceeds other borrowings | |||||||||||||||||||||||||||||||||
Payment other borrowings | |||||||||||||||||||||||||||||||||
Cash dividends | (40 | ) | 30 | ||||||||||||||||||||||||||||||
Equity sold | 203 | 71 | 97 | 36 | 45 | ||||||||||||||||||||||||||||
Other | 16 | 8 | (23 | ) | (16 | ) | (14 | ) | 15 | ||||||||||||||||||||||||
Cash provided by financing | (361 | ) | 1,362 | 7 | 653 | 668 | 571 | (727 | ) | ||||||||||||||||||||||||
Net Cash Flow | 172 | (158 | ) | (66 | ) | (68 | ) | (12 | ) | 6 | 106 | ||||||||||||||||||||||
Beginning Cash | 141 | 313 | 155 | 103 | 35 | 23 | 29 | ||||||||||||||||||||||||||
Ending Cash | 313 | 155 | 89 | 35 | 23 | 29 | 135 |
Page 38
Tenet Healthcare Corporation
Balance Sheet
($ in millions, except per share) | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | |||||||||||||||||||||||||
Assets | |||||||||||||||||||||||||||||||||
Current Assets: | |||||||||||||||||||||||||||||||||
Cash | 141 | 313 | 155 | 89 | 35 | 23 | 29 | 135 | |||||||||||||||||||||||||
Short-term investments | 98 | 60 | 139 | 112 | 116 | 132 | 130 | 110 | |||||||||||||||||||||||||
Accounts Receivable | 502 | 385 | 565 | 838 | 1,346 | 1,742 | 2,318 | 2,506 | |||||||||||||||||||||||||
Inventories of supplies | 62 | 55 | 116 | 128 | 193 | 214 | 221 | 223 | |||||||||||||||||||||||||
Deferred income taxes | 120 | 372 | 410 | 279 | 294 | 275 | 196 | 176 | |||||||||||||||||||||||||
Assets held for sale | 56 | 204 | 184 | 39 | 655 | 132 | |||||||||||||||||||||||||||
Prepaid expenses | 89 | 55 | 55 | 60 | 407 | 504 | 413 | 312 | |||||||||||||||||||||||||
Total current assets | 1,068 | 1,444 | 1,624 | 1,545 | 2,391 | 2,890 | 3,962 | 3,594 | |||||||||||||||||||||||||
Investments | 395 | 382 | 362 | 518 | 657 | 515 | 569 | 344 | |||||||||||||||||||||||||
PP&E, net | 2,492 | 1,764 | 3,319 | 3,648 | 5,459 | 6,014 | 5,839 | 5,894 | |||||||||||||||||||||||||
Intangible assets | 218 | 107 | 2,613 | 2,621 | 3,099 | 3,414 | 3,401 | 3,329 | |||||||||||||||||||||||||
4,173 | 3,697 | 7,918 | 8,332 | 11,606 | 12,833 | 13,771 | 13,161 | ||||||||||||||||||||||||||
Liabilities and Stockholders Equity | |||||||||||||||||||||||||||||||||
Current Liabilities: | |||||||||||||||||||||||||||||||||
Current LTD | 121 | 545 | 252 | 60 | 28 | 10 | 45 | 9 | |||||||||||||||||||||||||
Short-term borrowings | 163 | 67 | 35 | ||||||||||||||||||||||||||||||
Accounts payable | 140 | 176 | 359 | 380 | 540 | 657 | 713 | 671 | |||||||||||||||||||||||||
Accrued employee compensation | 104 | 93 | 162 | 120 | 309 | 355 | 390 | 383 | |||||||||||||||||||||||||
Accrued interest payable | 68 | 144 | 106 | 163 | 155 | ||||||||||||||||||||||||||||
Income taxes payable | 30 | 58 | 2 | 33 | |||||||||||||||||||||||||||||
Other current liabilities | 355 | 701 | 546 | 473 | 749 | 639 | 711 | 694 | |||||||||||||||||||||||||
Total current liabilities | 913 | 1,640 | 1,356 | 1,134 | 1,770 | 1,767 | 2,022 | 1,912 | |||||||||||||||||||||||||
LTD | 892 | 223 | 3,273 | 3,191 | 5,022 | 5,829 | 6,391 | 5,668 | |||||||||||||||||||||||||
Other Liabilities & minority interest | 299 | 389 | 1,002 | 977 | 1,282 | 1,256 | 1,048 | 1,024 | |||||||||||||||||||||||||
Deferred income taxes | 317 | 125 | 301 | 394 | 308 | 423 | 440 | 491 | |||||||||||||||||||||||||
Shareholders Equity | 1,752 | 1,320 | 1,986 | 2,636 | 3,224 | 3,558 | 3,870 | 4,066 | |||||||||||||||||||||||||
4,173 | 3,697 | 7,918 | 8,332 | 11,606 | 12,833 | 13,771 | 13,161 |
Page 39
1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | ||||||||||||||||||||||||||
ROA Operations | 5.3 | % | 3.4 | % | 3.5 | % | 3.9 | % | 4.4 | % | 3.9 | % | 4.2 | % | |||||||||||||||||||
ROC Operations | 10.0 | % | 5.8 | % | 5.2 | % | 5.6 | % | 6.1 | % | 5.2 | % | 5.6 | % | |||||||||||||||||||
ROE Operations | 13.6 | % | 12.0 | % | 12.4 | % | 13.4 | % | 15.8 | % | 13.9 | % | 14.2 | % | |||||||||||||||||||
ROA Total | -10.8 | % | 2.8 | % | 4.3 | % | -2.4 | % | 2.1 | % | 1.9 | % | 2.2 | % | |||||||||||||||||||
ROC Total | -20.3 | % | 4.9 | % | 6.3 | % | -3.5 | % | 3.0 | % | 2.5 | % | 3.0 | % | |||||||||||||||||||
ROE Total | -27.7 | % | 10.0 | % | 15.1 | % | -8.3 | % | 7.7 | % | 6.7 | % | 7.6 | % | |||||||||||||||||||
LTD : Equity | 0.51 | 0.17 | 1.65 | 1.21 | 1.56 | 1.64 | 1.65 | 1.39 | |||||||||||||||||||||||||
Total Debt : Equity | 0.67 | 0.63 | 1.79 | 1.23 | 1.57 | 1.64 | 1.66 | 1.40 | |||||||||||||||||||||||||
Total Debt : EBITDA | 2.30 | 1.51 | 5.71 | 2.96 | 3.31 | 3.23 | 3.46 | 2.93 | |||||||||||||||||||||||||
Interest Coverage | 6.81 | 7.89 | 4.51 | 3.52 | 3.65 | 3.90 | 3.83 | 4.04 | |||||||||||||||||||||||||
Cost of Debt Capital | 7.9 | % | 6.4 | % | 9.2 | % | 10.0 | % | 8.5 | % | 7.9 | % | 7.9 | % | |||||||||||||||||||
EBITDA / Share | $ | 3.08 | $ | 3.30 | $ | 3.52 | $ | 5.25 | $ | 5.01 | $ | 5.91 | $ | 5.99 | $ | 6.20 | |||||||||||||||||
EBITDA / Share Growth | 7.4 | % | 6.6 | % | 48.9 | % | -4.4 | % | 17.8 | % | 1.5 | % | 3.5 | % | |||||||||||||||||||
EBITDA Margin | 16.0 | % | 18.6 | % | 18.8 | % | 19.8 | % | 17.5 | % | 18.3 | % | 17.1 | % | 17.0 | % | |||||||||||||||||
D&A % Revenue | 5.0 | % | 5.4 | % | 5.9 | % | 5.8 | % | 5.1 | % | 4.6 | % | 5.1 | % | 4.7 | % | |||||||||||||||||
EBIT Margin | 11.0 | % | 13.2 | % | 12.9 | % | 14.0 | % | 12.4 | % | 13.6 | % | 12.0 | % | 12.3 | % | |||||||||||||||||
Interest % Revenue | 2.4 | % | 2.4 | % | 4.2 | % | 5.6 | % | 4.8 | % | 4.7 | % | 4.5 | % | 4.2 | % | |||||||||||||||||
Pretax Margin | 13.1 | % | 12.1 | % | 9.9 | % | 13.4 | % | 0.3 | % | 6.5 | % | 4.4 | % | 5.4 | % | |||||||||||||||||
Revenue Growth | -7.0 | % | 11.8 | % | 67.5 | % | 56.3 | % | 13.9 | % | 10.0 | % | 4.9 | % | |||||||||||||||||||
EBITDA Growth | 8.0 | % | 12.9 | % | 76.4 | % | 38.6 | % | 18.7 | % | 2.7 | % | 4.1 | % | |||||||||||||||||||
EPS Growth | -379.0 | % | -135.7 | % | 80.0 | % | -149.1 | % | -204.2 | % | -5.0 | % | 20.7 | % | |||||||||||||||||||
Capital Expenditures : Depreciation | 1.21 | 1.54 | 1.41 | 1.51 | |||||||||||||||||||||||||||||
Employees | 38,800 | 69,050 | 64,680 | 105,000 | 116,800 | 125,950 | 105,989 | ||||||||||||||||||||||||||
Regional / Divisional / Home Office Empl | 900 | 700 | 680 | 800 | 1,130 | 1,450 | 853 | ||||||||||||||||||||||||||
Revenue / Employee | 76 | 48 | 86 | 83 | 85 | 86 | 108 | ||||||||||||||||||||||||||
EBITDA / Employee | 14 | 9 | 17 | 15 | 15 | 15 | 18 | ||||||||||||||||||||||||||
Cash Flow Operations / Revenues | 5.0 | % | -0.2 | % | 3.5 | % | 4.6 | % | 4.1 | % | 5.3 | % | 7.6 | % | |||||||||||||||||||
Cash Flow Operations Cap Ex / Revenues | -1.3 | % | -8.2 | % | -3.1 | % | 0.0 | % | -1.3 | % | -0.1 | % | 2.2 | % | |||||||||||||||||||
Stock Price 5/31 | 9.500 | 16.375 | 16.625 | 21.500 | 27.500 | 35.000 | 24.500 | 25.625 | |||||||||||||||||||||||||
Stockholder Annual Return | 72.4 | % | 1.5 | % | 29.3 | % | 27.9 | % | 27.3 | % | -30.0 | % | 4.6 | % | |||||||||||||||||||
3 Year Return | 126.3 | % | 67.9 | % | 110.5 | % | 14.0 | % | -6.8 | % | |||||||||||||||||||||||
4 Year Return | 189.5 | % | 113.7 | % | 47.4 | % | 19.2 | % | |||||||||||||||||||||||||
5 Year Return | 268.4 | % | 49.6 | % | 54.1 | % | |||||||||||||||||||||||||||
Net A/R DSO | 57.4 | 47.4 | 62.2 | 55.0 | 56.5 | 64.3 | 77.8 | 80.1 | |||||||||||||||||||||||||
Change from Last Year | (10.1 | ) | 14.8 | (7.1 | ) | 1.5 | 7.7 | 13.5 | 2.4 | ||||||||||||||||||||||||
Change from 3 Years Ago | (2.4 | ) | 9.2 | 2.1 | 22.7 | 23.6 | |||||||||||||||||||||||||||
Cash Cost of 3 Year Change | 678 | 738 |
Page 40
HCA - The Healthcare Company
1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | ||||||||||||||||||||||||||
Years as Originally Reported ($ in millions, except per share) |
|||||||||||||||||||||||||||||||||
Revenues | 11,132 | 17,695 | 19,909 | 18,819 | 18,681 | 16,657 | 16,504 | ||||||||||||||||||||||||||
Salaries wages and benefits | 4,545 | 7,101 | 7,842 | 7,631 | 7,811 | 6,749 | 6,575 | ||||||||||||||||||||||||||
Supplies | 1,686 | 2,558 | 2,694 | 2,722 | 2,901 | 2,645 | 2,625 | ||||||||||||||||||||||||||
Other operating expenses | 2,059 | 3,418 | 4,025 | 4,263 | 3,771 | 3,196 | 3,067 | ||||||||||||||||||||||||||
Provision for doubtful accounts | 628 | 998 | 1,212 | 1,420 | 1,442 | 1,289 | 1,208 | ||||||||||||||||||||||||||
Equity in earnings of affiliates | (100 | ) | (173 | ) | (68 | ) | (112 | ) | (90 | ) | (115 | ) | |||||||||||||||||||||
EBITDA | 2,214 | 3,720 | 4,309 | 2,851 | 2,868 | 2,888 | 3,144 | ||||||||||||||||||||||||||
Depreciation and Amortization | 609 | 981 | 1,155 | 1,238 | 1,247 | 1,094 | 1,024 | ||||||||||||||||||||||||||
EBIT | 1,605 | 2,739 | 3,154 | 1,613 | 1,621 | 1,794 | 2,120 | ||||||||||||||||||||||||||
Interest expense (net) | 186 | 460 | 498 | 493 | 561 | 471 | 513 | ||||||||||||||||||||||||||
Merger and facility consolidation costs | 387 | 0 | (91 | ) | 0 | ||||||||||||||||||||||||||||
Minority interests consol sub | 29 | 113 | 141 | 150 | 70 | 57 | 95 | ||||||||||||||||||||||||||
Non-recurring transactions | 159 | 0 | 0 | 582 | 0 | 39 | 782 | ||||||||||||||||||||||||||
Income from conl. ops. (before tax) | 1,231 | 1,779 | 2,515 | 388 | 1,081 | 1,227 | 730 | ||||||||||||||||||||||||||
Provision for taxes | 486 | 715 | 1,010 | 206 | 549 | 570 | 344 | ||||||||||||||||||||||||||
Income from continuing operations | 745 | 1,064 | 1,505 | 182 | 532 | 657 | 386 | ||||||||||||||||||||||||||
Extra. loss on debt/Discon. Oper. | (115 | ) | 0 | 0 | (487 | ) | (153 | ) | 0 | ||||||||||||||||||||||||
Net Income | 630 | 1,064 | 1,505 | (305 | ) | 379 | 657 | 386 | |||||||||||||||||||||||||
EPS Continuing Operations | $ | 1.43 | $ | 1.58 | $ | 2.22 | $ | 0.28 | $ | 0.82 | $ | 1.12 | $ | 0.68 | |||||||||||||||||||
EPS, Investigation Charges | $ | | $ | | $ | | $ | | $ | | $ | | |||||||||||||||||||||
Discontinued operations | $ | (0.22 | ) | $ | | $ | | $ | (0.74 | ) | $ | (0.23 | ) | $ | | $ | | ||||||||||||||||
EPS, Fully Diluted | $ | 1.21 | $ | 1.58 | $ | 2.22 | $ | (0.46 | ) | $ | 0.59 | $ | 1.11 | $ | 0.68 | ||||||||||||||||||
Operating Pretax | 1,390 | 2,166 | 2,515 | 970 | 990 | 1,266 | 1,512 | ||||||||||||||||||||||||||
Operating Net | 834 | 1,300 | 1,509 | 582 | 594 | 760 | 907 | ||||||||||||||||||||||||||
Operating EPS | $ | 1.61 | $ | 1.93 | $ | 2.23 | $ | 0.88 | $ | 0.92 | $ | 1.30 | $ | 1.61 | |||||||||||||||||||
Basic Shares Outstanding | 519 | 673 | 678 | 663 | 643 | 585 | 563 | ||||||||||||||||||||||||||
Fully Diluted Shares Outstanding | 525 | 0 | 0 | 663 | 648 | 591 | 567 | ||||||||||||||||||||||||||
Expense Ratios: | |||||||||||||||||||||||||||||||||
Salaries wages and benefits | 40.8 | % | 40.1 | % | 39.4 | % | 40.5 | % | 41.8 | % | 40.5 | % | 39.8 | % | |||||||||||||||||||
Supplies | 15.1 | % | 14.5 | % | 13.5 | % | 14.5 | % | 15.5 | % | 15.9 | % | 15.9 | % | |||||||||||||||||||
Other operating expenses | 18.5 | % | 19.3 | % | 20.2 | % | 22.7 | % | 20.2 | % | 19.2 | % | 18.6 | % | |||||||||||||||||||
Provision for doubtful accounts | 5.6 | % | 5.6 | % | 6.1 | % | 7.5 | % | 7.7 | % | 7.6 | % | 7.3 | % | |||||||||||||||||||
EBIT Margin | 14.4 | % | 15.5 | % | 15.8 | % | 8.6 | % | 8.7 | % | 10.8 | % | 12.6 | % |
Page 41
Depreciation and amortization %ppe | 5.5% | 5.5% | 5.8% | 6.6% | 6.7% | 6.6% | 6.2% | |||||||
Tax Rate | 39.5% | 40.2% | 40.2% | 53.1% | 50.8% | 46.5% | 47.2% | |||||||
EBITDA Margin excl equity earnings | 19.9% | 20.5% | 20.8% | 14.8% | 14.8% | 16.8% | 18.4% | |||||||
EBITDA Margin | 19.9% | 21.0% | 21.6% | 15.1% | 15.4% | 17.3% | 19.0% |
Page 42
HCA The Healthcare Company
Cash Flow From Operations: | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||||||
Net income | 630 | 961 | 1,505 | (305 | ) | 379 | 657 | 386 | |||||||||||||||||||||||
Provision for doubtful accounts | 0 | 0 | 1,420 | 1,442 | 1,269 | 1,202 | |||||||||||||||||||||||||
Minority interests | 29 | 71 | 0 | 0 | 0 | ||||||||||||||||||||||||||
Depreciation & amortization | 609 | 981 | 1,155 | 1,238 | 1,247 | 1,094 | 1,024 | ||||||||||||||||||||||||
Merger/facility consolidation costs | 159 | 302 | (66 | ) | 873 | (49 | ) | (77 | ) | 0 | |||||||||||||||||||||
Amortization debt discount | 26 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||
Non cash taxes | (39 | ) | 15 | 0 | (163 | ) | 351 | (66 | ) | 163 | |||||||||||||||||||||
Extra, loss on debt refinancing | 187 | 170 | 0 | 56 | 0 | 0 | |||||||||||||||||||||||||
Working capital charges | (279 | ) | (275 | ) | (110 | ) | (1,640 | ) | (1,445 | ) | (1,692 | ) | (870 | ) | |||||||||||||||||
Other | (21 | ) | 29 | 137 | 4 | (9 | ) | 38 | 13 | ||||||||||||||||||||||
Cash Flow From Operations | 1,301 | 2,254 | 2,621 | 1,483 | 1,916 | 1,223 | 1,823 | ||||||||||||||||||||||||
Cash Flow From Investing | |||||||||||||||||||||||||||||||
Proceeds from asset sales | 86 | 334 | 166 | 212 | 2,060 | 805 | 38 | ||||||||||||||||||||||||
Hospital Acquisitions | (107 | ) | (1,333 | ) | (816 | ) | (411 | ) | (215 | ) | 0 | (18 | ) | ||||||||||||||||||
Capital expenditures | (975 | ) | (1,527 | ) | (1,400 | ) | (1,422 | ) | (1,255 | ) | (1,287 | ) | (1,022 | ) | |||||||||||||||||
Investments in/advances to affiliates | (226 | ) | (609 | ) | (61 | ) | (29 | ) | 383 | 886 | 0 | ||||||||||||||||||||
Other investing activity | (116 | ) | (283 | ) | (159 | ) | (36 | ) | (3 | ) | 521 | (198 | ) | ||||||||||||||||||
Other | (182 | ) | 19 | (1,060 | ) | 0 | 0 | 0 | |||||||||||||||||||||||
Cash Flow From Investing | (1,338 | ) | (3,600 | ) | (2,251 | ) | (2,746 | ) | 970 | 925 | (1,200 | ) | |||||||||||||||||||
Cash Flow From Financing | |||||||||||||||||||||||||||||||
Debt Paid Restructure | (146 | ) | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
Stock Used in Acquisitions | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Equity Issued | 18 | 42 | 0 | 8 | 0 | 0 | |||||||||||||||||||||||||
Issuance of LTD | 2,257 | 459 | 2,384 | (2,658 | ) | 1,037 | 1,200 | ||||||||||||||||||||||||
Payments LTD | (1,969 | ) | (303 | ) | (1,572 | ) | (550 | ) | |||||||||||||||||||||||
Borrowing under revolver | 1,230 | (579 | ) | 200 | (897 | ) | |||||||||||||||||||||||||
Payment of Dividends | (36 | ) | (50 | ) | (54 | ) | (53 | ) | (52 | ) | (44 | ) | (56 | ) | |||||||||||||||||
Other | (8 | ) | 0 | (12 | ) | 11 | 3 | 8 | 24 | ||||||||||||||||||||||
Purchase Treasury Stock | 0 | 0 | (1,082 | ) | 0 | (1,884 | ) | (242 | ) | ||||||||||||||||||||||
Cash Flow From Financing | (174 | ) | 1,510 | (489 | ) | 1,260 | (2,699 | ) | (2,255 | ) | (521 | ) | |||||||||||||||||||
Net Cash Flow | (211 | ) | 164 | (119 | ) | (3 | ) | 167 | (107 | ) | 102 | ||||||||||||||||||||
Beginning Cash | 224 | 68 | 232 | 113 | 110 | 124 | 292 | ||||||||||||||||||||||||
Ending Cash | 13 | 232 | 113 | 110 | 297 | 190 | 292 |
Page 43
HCA The Healthcare Company
Balance Sheet
($ in millions, except per share) | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||||||||
Current Assets | |||||||||||||||||||||||||||||||||
Cash | 13 | 232 | 113 | 110 | 297 | 190 | 292 | ||||||||||||||||||||||||||
Accounts Receivable | 1,747 | 2,665 | 3,023 | 2,522 | 2,096 | 1,873 | 1,937 | ||||||||||||||||||||||||||
Inventories of supplies | 285 | 406 | 441 | 452 | 434 | 383 | 360 | ||||||||||||||||||||||||||
Deferred income taxes | 113 | 0 | 532 | 149 | 178 | 180 | |||||||||||||||||||||||||||
Other | 505 | 784 | 836 | 807 | 887 | 973 | 901 | ||||||||||||||||||||||||||
Total Current Assets | 2,550 | 4,200 | 4,413 | 4,423 | 3,863 | 3,597 | 3,671 | ||||||||||||||||||||||||||
Investments | 888 | 2,092 | 2,412 | 2,751 | 2,889 | 2,111 | 2,192 | ||||||||||||||||||||||||||
PP&E, net | 6,383 | 9,751 | 10,399 | 10,230 | 9,449 | 8,490 | 8,830 | ||||||||||||||||||||||||||
Intangible assets | 2,269 | 3,497 | 3,709 | 3,521 | 2,910 | 2,319 | 2,341 | ||||||||||||||||||||||||||
Other | 249 | 352 | 339 | 1,077 | 318 | 368 | 388 | ||||||||||||||||||||||||||
12,339 | 19,892 | 21,272 | 22,002 | 19,429 | 16,885 | 17,422 | |||||||||||||||||||||||||||
Current Liabilities | |||||||||||||||||||||||||||||||||
Current LTD | 77 | 243 | 201 | 132 | 1,068 | 1,160 | 691 | ||||||||||||||||||||||||||
Accounts payable | 503 | 829 | 845 | 929 | 784 | 657 | 676 | ||||||||||||||||||||||||||
Salaries, wages, and other compensation | 277 | 520 | 453 | 475 | 425 | 403 | 360 | ||||||||||||||||||||||||||
Other current liabilities | 910 | 1,146 | 1,320 | 1,237 | 1,282 | 1,112 | 1,802 | ||||||||||||||||||||||||||
Income taxes | 0 | 127 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Total Current Liabilities | 1,767 | 2,738 | 2,946 | 2,773 | 3,559 | 3,332 | 3,529 | ||||||||||||||||||||||||||
LTD | 3,853 | 7,137 | 6,781 | 9,276 | 5,685 | 5,284 | 5,776 | ||||||||||||||||||||||||||
Deferred credits and other liabilities | 1,439 | 2,166 | 2,100 | 1,867 | 1,839 | 1,889 | 1,667 | ||||||||||||||||||||||||||
Deferred income taxes | 258 | 722 | 836 | 836 | 765 | 763 | 739 | ||||||||||||||||||||||||||
Minority interest | 5,022 | 7,129 | 8,609 | 7,250 | 7,581 | 5,617 | 5,711 | ||||||||||||||||||||||||||
Shareholder Equity | 12,339 | 19,892 | 21,272 | 22,002 | 19,429 | 16,885 | 17,422 |
Page 44
1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||||||||
ROA - Operations | 8.1% | 7.3% | 2.7% | 2.9% | 4.2% | 5.3% | ||||||||||||||||||||||||||
ROC - Operations | 11.2% | 10.2% | 3.6% | 4.0% | 6.3% | 8.1% | ||||||||||||||||||||||||||
ROE - Operations | 21.4% | 19.2% | 7.3% | 8.0% | 11.5% | 16.0% | ||||||||||||||||||||||||||
ROA - Total | 6.6% | 7.3% | -1.4% | 1.8% | 3.6% | 2.3% | ||||||||||||||||||||||||||
ROC - Total | 9.2% | 10.1% | -1.9% | 2.5% | 5.4% | 3.4% | ||||||||||||||||||||||||||
ROE - Total | 17.5% | 19.1% | -3.8% | 5.1% | 10.0% | 8.8% | ||||||||||||||||||||||||||
LTD : Equity | 0.77 | 1.00 | 0.79 | 1.28 | 0.75 | 0.94 | 1.01 | |||||||||||||||||||||||||
Total Debt : Equity | 0.78 | 1.04 | 0.81 | 1.30 | 0.89 | 1.15 | 1.13 | |||||||||||||||||||||||||
Total Debt : EBITDA | 1.78 | 1.98 | 1.62 | 3.30 | 2.35 | 2.23 | 2.06 | |||||||||||||||||||||||||
Interest Coverage | 11.90 | 8.09 | 8.65 | 5.78 | 5.11 | 6.13 | 6.13 | |||||||||||||||||||||||||
Cost of Debt Capital | 8.1% | 6.9% | 6.0% | 6.9% | 7.1% | 7.9% | ||||||||||||||||||||||||||
EBITDA / Share | $ | 4.26 | $ | 5.53 | $ | 6.36 | $ | 4.30 | $ | 4.46 | $ | 4.93 | $ | 5.58 | ||||||||||||||||||
EBITDA / Share Growth | 29.6% | 15.0% | -32.4% | 3.7% | 10.7% | 13.1% | ||||||||||||||||||||||||||
EBITDA Margin | 19.9% | 21.0% | 21.6% | 15.1% | 15.4% | 17.3% | 19.0% | |||||||||||||||||||||||||
D&A % Revenue | 5.5% | 5.5% | 5.8% | 6.6% | 6.7% | 6.6% | 6.2% | |||||||||||||||||||||||||
EBIT Margin | 14.4% | 15.5% | 15.8% | 6.6% | 8.7% | 10.8% | 12.8% | |||||||||||||||||||||||||
Interest % Revenue | 1.7% | 2.6% | 2.5% | 2.6% | 3.0% | 2.8% | 3.1% | |||||||||||||||||||||||||
Pretax Margin | 11.1% | 10.1% | 12.6% | 2.1% | 5.8% | 7.4% | 4.4% | |||||||||||||||||||||||||
Revenue Growth | 59.0% | 12.5% | -5.5% | -0.7% | -10.8% | -0.9% | ||||||||||||||||||||||||||
EBITDA Growth | 68.0% | 15.8% | -33.8% | 0.6% | 0.7% | 8.9% | ||||||||||||||||||||||||||
EPS Growth | 10.2% | 40.4% | -87.4% | 192.9% | 36.6% | -39.2% | ||||||||||||||||||||||||||
Capital Expenditures : Depreciation | 1.56 | 1.21 | 1.15 | 1.01 | 1.18 | 1.00 | ||||||||||||||||||||||||||
Employees | 295,000 | 260,000 | 168,000 | 165,000 | ||||||||||||||||||||||||||||
Regional / Divisional / Home Office Empl | ||||||||||||||||||||||||||||||||
Revenue / Employee | 64 | 72 | 99 | 100 | ||||||||||||||||||||||||||||
EBITDA / Employee | 10 | 11 | 17 | 19 | ||||||||||||||||||||||||||||
Cash Flow Operations / Revenues | 12.7% | 13.2% | 7.9% | 10.3% | 7.3% | 11.0% | ||||||||||||||||||||||||||
Cash Flow Operations - Cap Ex / Revenues | 4.1% | 6.1% | 0.3% | 3.5% | -0.4% | 4.9% | ||||||||||||||||||||||||||
Stock Price 12/31 | 22.083 | 24.333 | 33.833 | 40.750 | 29.625 | 24.750 | 29.312 | 31.750 | ||||||||||||||||||||||||
Stockholder Annual Return | 10.2% | 39.0% | 20.4% | -27.3% | -16.5% | 18.4% | 8.3% | |||||||||||||||||||||||||
3 Year Return | 84.5% | 21.7% | -26.8% | -28.1% | 7.2% | |||||||||||||||||||||||||||
4 Year Return | 34.2% | 1.7% | -13.4% | -22.1% | ||||||||||||||||||||||||||||
5 Year Return | 12.1% | 20.5% | -6.2% | |||||||||||||||||||||||||||||
Net A/R DSO | 57.3 | 55.0 | 55.4 | 48.9 | 41.0 | 41.0 | 42.8 | |||||||||||||||||||||||||
Change from Last Year | (2.3 | ) | 0.5 | (6.5 | ) | (8.0 | ) | 0.1 | 1.8 | |||||||||||||||||||||||
Change from 3 Years Ago | (8.4 | ) | (14.0 | ) | (14.4 | ) | (6.1 | ) | ||||||||||||||||||||||||
Cash Cost of 3 Year Change | (656 | ) | (274 | ) |
Page 45
Universal Health Services
1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||||||||||
Years as Originally Reported ($ in millions, except per share) |
||||||||||||||||||||||||||||||||||
Net revenues | 782 | 931 | 1,190 | 1,443 | 1,874 | 2,042 | 2,131 | |||||||||||||||||||||||||||
Operating Charges: | ||||||||||||||||||||||||||||||||||
Operating expenses | 643 | 771 | 458 | 575 | 753 | 829 | 853 | |||||||||||||||||||||||||||
Salaries & wages | 0 | 0 | 421 | 514 | 671 | 729 | 773 | |||||||||||||||||||||||||||
Provision for doubtful accounts | 0 | 0 | 97 | 109 | 140 | 166 | 172 | |||||||||||||||||||||||||||
EBITDAR | 139 | 161 | 215 | 244 | 311 | 319 | 333 | |||||||||||||||||||||||||||
Lease and rental expense | 34 | 36 | 37 | 38 | 47 | 49 | 48 | |||||||||||||||||||||||||||
Nonrecurring charges | 10 | 9 | 4 | 0 | 0 | 5 | 0 | |||||||||||||||||||||||||||
EBITDA | 96 | 116 | 173 | 206 | 265 | 264 | 284 | |||||||||||||||||||||||||||
Depreciation and amortization | 42 | 51 | 72 | 81 | 105 | 108 | 102 | |||||||||||||||||||||||||||
EBITDA | 53 | 64 | 101 | 125 | 159 | 156 | 183 | |||||||||||||||||||||||||||
Interest expense | 6 | 11 | 21 | 19 | 27 | 27 | 32 | |||||||||||||||||||||||||||
Minority interest | 0 | 0 | 0 | 0 | 9 | 6 | 12 | |||||||||||||||||||||||||||
Income before income taxes | 47 | 53 | 80 | 106 | 123 | 123 | 139 | |||||||||||||||||||||||||||
Provision for income taxes | 16 | 18 | 29 | 39 | 43 | 45 | 50 | |||||||||||||||||||||||||||
Net income | 29 | 35 | 51 | 67 | 80 | 78 | 89 | |||||||||||||||||||||||||||
Net Income Excluding Extraordinary Charges | 0 | 0 | 0 | 67 | 81 | 78 | 89 | |||||||||||||||||||||||||||
E.P.S. Fully Diluted | $ | 1.00 | $ | 1.26 | $ | 1.64 | $ | 2.03 | $ | 2.39 | $ | 2.43 | $ | 2.91 | ||||||||||||||||||||
E.P.S. Fully Diluted excluding extraordinary charges | $ | | $ | | $ | | $ | 2.03 | $ | 2.44 | $ | 2.43 | $ | 2.91 | ||||||||||||||||||||
Shares Outstanding - Primary | 29 | 28 | 31 | 33 | 33 | 31 | 30 | |||||||||||||||||||||||||||
Shares Outstanding - Fully Diluted | 0 | 0 | 0 | 33 | 33 | 32 | 31 | |||||||||||||||||||||||||||
Operating Pretax | 57 | 62 | 84 | 106 | 123 | 128 | 139 | |||||||||||||||||||||||||||
Operating Net | 36 | 39 | 53 | 67 | 78 | 81 | 88 | |||||||||||||||||||||||||||
Operating EPS | $ | 1.25 | $ | 1.40 | $ | 1.73 | $ | 2.03 | $ | 2.40 | $ | 2.59 | $ | 2.93 | ||||||||||||||||||||
Margin Analysis | ||||||||||||||||||||||||||||||||||
Operating Expenses | 0.0% | 0.0% | 38.5% | 39.9% | 40.2% | 40.6% | 40.0% | |||||||||||||||||||||||||||
Salaries & wages | 0.0% | 0.0% | 35.3% | 35.7% | 35.8% | 35.7% | 36.3% | |||||||||||||||||||||||||||
Provision for doubtful accounts | 0.0% | 0.0% | 8.1% | 7.5% | 7.4% | 8.1% | 8.1% | |||||||||||||||||||||||||||
EBITDAR | 17.8% | 17.2% | 18.0% | 16.9% | 16.6% | 15.6% | 15.6% | |||||||||||||||||||||||||||
Lease and rental expense | 4.4% | 3.9% | 3.1% | 2.7% | 2.5% | 2.4% | 2.3% | |||||||||||||||||||||||||||
EBITDA | 12.2% | 12.4% | 14.6% | 14.3% | 14.1% | 12.9% | 13.3% | |||||||||||||||||||||||||||
Depreciation and amortization | 5.4% | 5.5% | 6.0% | 5.6% | 5.6% | 5.3% | 4.8% | |||||||||||||||||||||||||||
Tax Rate | 38.8% | 33.0% | 36.7% | 36.5% | 35.3% | 36.7% | 35.8% | |||||||||||||||||||||||||||
D&A as % PPE | 6.7% | 6.8% | 7.3% | 7.1% | 7.1% | 7.3% | 8.0% |
Page 46
Universal Health Services
1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | ||||||||||||||||||||||||||
Cash Flows from Operating Activities: | |||||||||||||||||||||||||||||||||
Net income | 29 | 35 | 51 | 67 | 80 | 78 | 89 | ||||||||||||||||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities: | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Depreciation & amortization | 42 | 51 | 72 | 61 | 105 | 108 | 102 | ||||||||||||||||||||||||||
Provision for self-insurance reserves | 11 | 14 | 16 | 19 | 9 | 6 | 16 | ||||||||||||||||||||||||||
Reserve for loss on disposition of businesses | 0 | 0 | 0 | 0 | 0 | 5 | 0 | ||||||||||||||||||||||||||
Other non cash charges | 10 | 12 | 4 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||
Changes in assets & liabilities, net of effects from acquisitions and dispositions: | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||
Accounts receivable | (4 | ) | (5 | ) | (0 | ) | (15 | ) | (21 | ) | (38 | ) | (32 | ) | |||||||||||||||||||
Accrued interest | (1 | ) | 3 | (1 | ) | (3 | ) | 0 | (0 | ) | (4 | ) | |||||||||||||||||||||
Accrued and deferred income taxes | (10 | ) | (21 | ) | 16 | 7 | 0 | (3 | ) | 15 | |||||||||||||||||||||||
Other working capital accounts | 2 | 11 | 3 | 34 | (2 | ) | 32 | (11 | ) | ||||||||||||||||||||||||
Other assets and deferred charges | (3 | ) | (4 | ) | (5 | ) | 6 | 1 | 10 | 4 | |||||||||||||||||||||||
Other | (0 | ) | 3 | (3 | ) | 6 | 1 | 10 | 4 | ||||||||||||||||||||||||
Payments made in settlement of self insurance claims | (15 | ) | (6 | ) | (8 | ) | (16 | ) | (14 | ) | (18 | ) | (3 | ) | |||||||||||||||||||
Net cash provided by operating activities | 61 | 92 | 145 | 158 | 143 | 176 | 200 | ||||||||||||||||||||||||||
Cash Flows from Investing Activities: | |||||||||||||||||||||||||||||||||
Property and equipment additions | (44 | ) | (61 | ) | (106 | ) | (144 | ) | (97 | ) | (68 | ) | (130 | ) | |||||||||||||||||||
Disposition of assets | 1 | 2 | 2 | 4 | 11 | 16 | 3 | ||||||||||||||||||||||||||
Acquisition of property previously leased | (6 | ) | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
Acquisition of businesses | (17 | ) | (166 | ) | (158 | ) | (191 | ) | (189 | ) | (32 | ) | (142 | ) | |||||||||||||||||||
Advances under long term notes receivable | 0 | 0 | (7 | ) | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
Acquisition of assets held for lease | (9 | ) | (4 | ) | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||
Disposition of businesses | 4 | 19 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||
Other investments | (1 | ) | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
Net cash used in investing activities | (72 | ) | (230 | ) | (279 | ) | (331 | ) | (275 | ) | (83 | ) | (269 | ) | |||||||||||||||||||
Cash Flows from Financing Activities: | |||||||||||||||||||||||||||||||||
Additional borrowings | 45 | 149 | 42 | 0 | 0 | 15 | 0 | ||||||||||||||||||||||||||
Reduction of long-term debt | (22 | ) | (12 | ) | (8 | ) | 178 | 138 | (16 | ) | 75 | ||||||||||||||||||||||
Distribution to minority partners | 0 | 0 | 0 | 0 | 0 | (16 | ) | 0 | |||||||||||||||||||||||||
Issuance of common stock | 1 | 1 | 100 | 1 | 1 | 3 | 0 | ||||||||||||||||||||||||||
Repurchase of common stock | (13 | ) | 0 | 0 | 0 | (6 | ) | (71 | ) | (7 | ) | ||||||||||||||||||||||
Net cash provided by (used in) financing activities | 11 | 138 | 134 | 180 | 133 | (68 | ) | 68 |
Page 47
1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||||||||
Increase (Decrease) in cash and cash equivalents | 0 | (1 | ) | 0 | 8 | 1 | 5 | (1 | ) | |||||||||||||||||||||||
Cash and cash equivalents, Beginning of Period | 11 | 1 | 0 | 0 | 0 | 1 | 6 | |||||||||||||||||||||||||
Cash and cash equivalents, End of Period | 11 | 0 | 0 | 8 | 1 | 6 | 6 |
Page 48
Universal Health Services
Assets | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | ||||||||||||||||||||||||||
Current Assets: | ||||||||||||||||||||||||||||||||||
Cash and cash equivalents | 1 | 0 | 0 | 0 | 1 | 6 | 6 | |||||||||||||||||||||||||||
Accounts receivable, net | 85 | 114 | 145 | 180 | 256 | 307 | 338 | |||||||||||||||||||||||||||
Supplies | 16 | 18 | 22 | 28 | 39 | 41 | 43 | |||||||||||||||||||||||||||
Deferred income taxes | 13 | 19 | 12 | 11 | 11 | 27 | 0 | |||||||||||||||||||||||||||
Other current assets | 4 | 6 | 14 | 10 | 12 | 22 | 89 | |||||||||||||||||||||||||||
Total current assets | 118 | 157 | 194 | 230 | 320 | 403 | 475 | |||||||||||||||||||||||||||
Property and equipment | 597 | 618 | 840 | 992 | 1,205 | 1,215 | 935 | |||||||||||||||||||||||||||
Less: accumulated depreciation | (265 | ) | (225 | ) | (272 | ) | (329 | ) | (397 | ) | (436 | ) | (46 | ) | ||||||||||||||||||||
Other assets: | ||||||||||||||||||||||||||||||||||
Excess of cost over fair value of net assets acquired | 39 | 136 | 150 | 150 | 279 | 276 | 336 | |||||||||||||||||||||||||||
Deferred charges | 2 | 29 | 10 | 11 | 14 | 11 | 0 | |||||||||||||||||||||||||||
Other | 31 | 33 | 44 | 32 | 27 | 31 | 41 | |||||||||||||||||||||||||||
Liabilities and Stockholders Equity | 521 | 748 | 966 | 1,085 | 1,448 | 1,498 | 1,741 | |||||||||||||||||||||||||||
Current liabilities: | ||||||||||||||||||||||||||||||||||
Current maturities of long term debt | 7 | 7 | 7 | 6 | 4 | 4 | 1 | |||||||||||||||||||||||||||
Accounts payable and accrued liabilities | 92 | 126 | 132 | 153 | 156 | 214 | 230 | |||||||||||||||||||||||||||
Federal and state taxes | 4 | 2 | 1 | 2 | 10 | 0 | 76 | |||||||||||||||||||||||||||
Total current liabilities | 104 | 135 | 140 | 160 | 170 | 217 | 307 | |||||||||||||||||||||||||||
Deferred income taxes | 0 | 0 | 0 | 0 | 23 | 31 | 36 | |||||||||||||||||||||||||||
Other noncurrent liabilities | 72 | 78 | 97 | 126 | 210 | 189 | 128 | |||||||||||||||||||||||||||
Long term debt, net of current maturities | 85 | 237 | 276 | 272 | 418 | 419 | 553 | |||||||||||||||||||||||||||
Common stockholders equity: | ||||||||||||||||||||||||||||||||||
Class A Common Stock, 2,057,929 shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
outstanding in 1998, 2,059,929 in 1997 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Class B Common Stock, 29,901,218 shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
outstanding in 1998, 30,122,479 in 1997 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Class C Common Stock, 207,230 shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
outstanding in 1998, 207,230 in 1997 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Class D Common Stock, 28,786 shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
outstanding in 1998, 32,063 shares in 1997 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Capital in excess of par, net of deferred compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
of $185 in 1998 and $295 in 1997 | 88 | 90 | 194 | 201 | 222 | 158 | 0 | |||||||||||||||||||||||||||
Retained earnings | 172 | 208 | 258 | 328 | 405 | 483 | 717 | |||||||||||||||||||||||||||
261 | 298 | 453 | 527 | 627 | 642 | 717 | ||||||||||||||||||||||||||||
Total Liabilities & Equity | 521 | 748 | 966 | 1,085 | 1,448 | 1,498 | 1,741 |
Page 49
1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||||||||
ROA Operations | 6.2% | 6.2% | 6.6% | 6.2% | 5.5% | 5.4% | ||||||||||||||||||||||||||
ROC Operations | 8.9% | 8.5% | 8.8% | 8.5% | 7.7% | 7.6% | ||||||||||||||||||||||||||
ROE Operations | 14.1% | 14.2% | 13.7% | 13.5% | 12.8% | 13.0% | ||||||||||||||||||||||||||
ROA Total | 5.6% | 5.9% | 6.6% | 6.3% | 5.3% | 5.5% | ||||||||||||||||||||||||||
ROC Total | 8.1% | 8.0% | 8.8% | 8.6% | 7.4% | 7.6% | ||||||||||||||||||||||||||
ROE Total | 12.7% | 13.5% | 13.7% | 13.8% | 12.3% | 13.1% | ||||||||||||||||||||||||||
LTD: Equity | 0.33 | 0.80 | 0.61 | 0.52 | 0.67 | 0.65 | 0.77 | |||||||||||||||||||||||||
Total Debt: Equity | 0.35 | 0.82 | 0.62 | 0.53 | 0.67 | 0.66 | 0.77 | |||||||||||||||||||||||||
Total Debt: EBITDA | 0.97 | 2.11 | 1.63 | 1.35 | 1.60 | 1.60 | 1.95 | |||||||||||||||||||||||||
Interest Coverage | 15.23 | 10.32 | 8.15 | 10.63 | 9.76 | 9.83 | 8.92 | |||||||||||||||||||||||||
Cost of Debt Capital | 6.7% | 8.1% | 6.9% | 7.7% | 6.4% | 6.5% | ||||||||||||||||||||||||||
EBITDA / Share | $ | 3.32 | $ | 4.10 | $ | 5.61 | $ | 6.22 | $ | 8.14 | $ | 8.41 | $ | 9.46 | ||||||||||||||||||
EBITDA / Share Growth | 23.6% | 36.8% | 10.8% | 30.8% | 3.3% | 12.5% | ||||||||||||||||||||||||||
EBITDA Margin | 12.2% | 12.4% | 14.6% | 14.3% | 14.1% | 12.9% | 13.3% | |||||||||||||||||||||||||
D&A % Revenue | 5.4% | 5.5% | 6.0% | 5.6% | 5.6% | 5.3% | 4.8% | |||||||||||||||||||||||||
EBIT Margin | 6.6% | 6.9% | 8.5% | 8.7% | 8.5% | 7.6% | 8.6% | |||||||||||||||||||||||||
Interest % Revenue | 0.8% | 1.2% | 1.8% | 1.3% | 1.4% | 1.3% | 1.5% | |||||||||||||||||||||||||
Pretax Margin | 6.0% | 5.7% | 6.7% | 7.3% | 6.6% | 6.0% | 6.5% | |||||||||||||||||||||||||
Revenue Growth | 19.0% | 27.8% | 21.2% | 29.9% | 9.0% | 4.3% | ||||||||||||||||||||||||||
EBITDA Growth | 15.1% | 33.7% | 13.8% | 27.3% | 2.4% | 4.4% | ||||||||||||||||||||||||||
EPS Growth | 26.3% | 30.3% | 23.7% | 17.6% | 1.7% | 19.6% | ||||||||||||||||||||||||||
Capital Expenditures: Depreciation | 1.04 | 1.18 | 1.47 | 1.78 | 0.92 | 0.62 | 1.28 | |||||||||||||||||||||||||
Employees | 17,800 | 19,200 | 19,350 | 20,000 | ||||||||||||||||||||||||||||
Regional / Divisional / Home Office Employee | ||||||||||||||||||||||||||||||||
Revenue / Employee | 81 | 98 | 106 | 107 | ||||||||||||||||||||||||||||
EBITDA / Employee | 12 | 14 | 14 | 14 | ||||||||||||||||||||||||||||
Cash Flow Operations / Revenues | 7.8% | 9.9% | 12.2% | 11.0% | 7.6% | 8.6% | 9.4% | |||||||||||||||||||||||||
Cash Flow Operations Cap Ex / Revenues | 2.1% | 3.3% | 3.3% | 1.0% | 2.5% | 5.3% | 3.3% | |||||||||||||||||||||||||
Stock Price 12/31 | 10.125 | 12.250 | 22.188 | 28.625 | 50.375 | 51.875 | 36.000 | 67.938 | ||||||||||||||||||||||||
Stockholder Annual Return | 21.0% | 81.1% | 29.0% | 76.0% | 3.0% | -30.6% | 88.7% | |||||||||||||||||||||||||
3 Year Return | 182.7% | 311.2% | 133.8% | 25.8% | 34.9% | |||||||||||||||||||||||||||
4 Year Return | 397.5% | 323.5% | 62.3% | 137.3% | ||||||||||||||||||||||||||||
5 Year Return | 412.3% | 193.9% | 206.2% | |||||||||||||||||||||||||||||
Net A/R DSO | 39.6 | 44.8 | 44.6 | 45.6 | 49.9 | 54.9 | 57.9 | |||||||||||||||||||||||||
Change from Last Year | 5.2 | (0.2 | ) | 1.0 | 4.3 | 5.0 | 2.9 | |||||||||||||||||||||||||
Change from 3 Years Ago | 6.0 | 5.2 | 10.3 | 12.3 | ||||||||||||||||||||||||||||
Cash Cost of 3 Year Change | 58 | 72 |
Page 50
Health Management Associates
Income Statement | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | ||||||||||||||||||||||||||
Years as Originally Reported | ||||||||||||||||||||||||||||||||||
($ in millions, except per share) | ||||||||||||||||||||||||||||||||||
Net patient service revenues | 438 | 531 | 714 | 895 | 1,139 | 1,356 | 1,620 | |||||||||||||||||||||||||||
Costs and expenses | ||||||||||||||||||||||||||||||||||
Salaries and benefits | 149 | 179 | 248 | 311 | 402 | 486 | 585 | |||||||||||||||||||||||||||
Supplies and other | 135 | 162 | 216 | 270 | 331 | 390 | 475 | |||||||||||||||||||||||||||
Provision for doubtful accounts | 40 | 48 | 65 | 77 | 96 | 130 | 140 | |||||||||||||||||||||||||||
EBITDAR | 114 | 141 | 185 | 238 | 307 | 349 | 420 | |||||||||||||||||||||||||||
Rents | 11 | 13 | 16 | 19 | 27 | 33 | 39 | |||||||||||||||||||||||||||
Total operating expenses | 336 | 403 | 545 | 677 | 858 | 1,039 | 1,239 | |||||||||||||||||||||||||||
EBITDA | 103 | 128 | 169 | 219 | 280 | 316 | 381 | |||||||||||||||||||||||||||
Depreciation and amortization | 17 | 21 | 27 | 37 | 50 | 61 | 76 | |||||||||||||||||||||||||||
EBIT | 86 | 108 | 142 | 182 | 230 | 255 | 304 | |||||||||||||||||||||||||||
Interest expense | 4 | 4 | 4 | 4 | 5 | 8 | 27 | |||||||||||||||||||||||||||
Income before income taxes | 82 | 104 | 138 | 178 | 225 | 247 | 278 | |||||||||||||||||||||||||||
Provision for income taxes | 33 | 41 | 54 | 70 | 88 | 97 | 109 | |||||||||||||||||||||||||||
Cumulative effect of change in accounting for | ||||||||||||||||||||||||||||||||||
income taxes | (3 | ) | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||
Net income | 47 | 63 | 84 | 108 | 137 | 150 | 169 | |||||||||||||||||||||||||||
Net income per share: | $ | | $ | | $ | | $ | | $ | | $ | | $ | | ||||||||||||||||||||
Income before accounting change | $ | 0.21 | $ | 0.26 | $ | 0.34 | $ | 0.43 | $ | 0.54 | $ | 0.60 | $ | 0.70 | ||||||||||||||||||||
Accounting change | $ | (0.01 | ) | $ | | $ | | $ | | $ | | $ | | $ | | |||||||||||||||||||
Net income per share | $ | 0.20 | $ | 0.26 | $ | 0.34 | $ | 0.43 | $ | 0.54 | $ | 0.60 | $ | 0.69 | ||||||||||||||||||||
Weighted average number of common shares | ||||||||||||||||||||||||||||||||||
and common equivalents shares outstanding | 236 | 239 | 244 | 249 | 256 | 250 | 242 | |||||||||||||||||||||||||||
Margin Analysis | ||||||||||||||||||||||||||||||||||
Salaries and benefits | 34.1% | 33.8% | 34.7% | 34.7% | 35.3% | 35.8% | 36.1% | |||||||||||||||||||||||||||
Supplies and other | 30.8% | 30.5% | 30.3% | 30.1% | 29.1% | 28.8% | 29.3% | |||||||||||||||||||||||||||
Provision for doubtful accounts | 9.1% | 9.1% | 9.1% | 8.6% | 8.6% | 9.6% | 8.6% | |||||||||||||||||||||||||||
EBITDAR margin | 26.0% | 26.6% | 25.9% | 26.6% | 27.0% | 25.8% | 25.9% | |||||||||||||||||||||||||||
Rents | 2.6% | 2.4% | 2.3% | 2.2% | 2.4% | 2.4% | 2.4% | |||||||||||||||||||||||||||
Total operating expenses | 76.5% | 75.8% | 76.3% | 75.6% | 75.4% | 76.7% | 76.5% | |||||||||||||||||||||||||||
EBITDA Margin | 23.5% | 24.2% | 23.7% | 24.4% | 24.6% | 23.3% | 23.5% | |||||||||||||||||||||||||||
Depreciation | 3.8% | 3.9% | 3.8% | 4.1% | 4.4% | 4.5% | 4.7% | |||||||||||||||||||||||||||
EBIT Margin | 19.7% | 20.3% | 19.9% | 20.3% | 20.2% | 18.8% | 18.8% | |||||||||||||||||||||||||||
Pretax Margin | 18.6% | 18.6% | 18.6% | 18.6% | 18.6% | 18.6% | 18.6% |
Page 51
Tax Rate | 39.9 | % | 39.3 | % | 39.2 | % | 39.2 | % | 39.3 | % | 39.2 | % | 39.3 | % | ||||||||||||||
Depreciation % of PP&E | 0.0 | % | 0.0 | % | 0.0 | % | 0.0 | % | 0.0 | % | 0.0 | % | 0.0 | % |
Page 52
Health Management Associates
Cash Flow Statement ($ in thousands)
Cash Flows from Operating Activities: | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | ||||||||||||||||||||||||||
Net Income | 47 | 63 | 84 | 108 | 137 | 150 | 169 | |||||||||||||||||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||||||||||||||||||||||
Depreciation & amortization | 17 | 21 | 27 | 37 | 50 | 61 | 76 | |||||||||||||||||||||||||||
Cummulative effect of change in accounting for income taxes | 3 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Loss on sale of fixed assets | (0 | ) | 0 | 0 | (0 | ) | (0 | ) | 0 | 0 | ||||||||||||||||||||||||
Decrease in Deferred and other income taxes | (1 | ) | (1 | ) | 1 | (0 | ) | 0 | (5 | ) | 0 | |||||||||||||||||||||||
Changes in assets & liabilities, net of effects from acquisitions and dispositions: | ||||||||||||||||||||||||||||||||||
Accounts receivable | (21 | ) | (12 | ) | (20 | ) | (13 | ) | (50 | ) | (65 | ) | (17 | ) | ||||||||||||||||||||
Increase in other current assets | (1 | ) | (1 | ) | (1 | ) | (3 | ) | (28 | ) | (8 | ) | (81 | ) | ||||||||||||||||||||
Deferred charges and other assets | (3 | ) | (3 | ) | (7 | ) | (3 | ) | (4 | ) | 0 | (7 | ) | |||||||||||||||||||||
Accounts payable | 1 | 6 | 3 | 2 | 4 | 23 | 19 | |||||||||||||||||||||||||||
Accrued expenses and other liabilities | 0 | 3 | 1 | 5 | 9 | 3 | 19 | |||||||||||||||||||||||||||
Income taxes currently payable and deferred | 3 | (3 | ) | 3 | (1 | ) | 8 | 10 | (13 | ) | ||||||||||||||||||||||||
Other long term liabilities | 3 | 1 | 3 | 1 | 0 | (1 | ) | 0 | ||||||||||||||||||||||||||
Net cash provided by operating activities | 46 | 74 | 95 | 132 | 127 | 168 | 167 | |||||||||||||||||||||||||||
Cash Flows from Investing Activities: | ||||||||||||||||||||||||||||||||||
Acquisition of facility | (1 | ) | (74 | ) | (100 | ) | (51 | ) | (168 | ) | (184 | ) | (60 | ) | ||||||||||||||||||||
Additions to property, plant and equipment | (23 | ) | (23 | ) | (41 | ) | (59 | ) | (54 | ) | (159 | ) | (112 | ) | ||||||||||||||||||||
Proceeds from sale of equipment | 5 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Net cash used in investing activities | (19 | ) | (97 | ) | (141 | ) | (110 | ) | (222 | ) | (343 | ) | (172 | ) | ||||||||||||||||||||
Cash Flows from Financing Activities: | ||||||||||||||||||||||||||||||||||
Proceeds from long term borrowings | 7 | 1 | 1 | 1 | 58 | 250 | 73 | |||||||||||||||||||||||||||
Principal payments on debt | (10 | ) | (14 | ) | (7 | ) | (21 | ) | (22 | ) | (17 | ) | (15 | ) | ||||||||||||||||||||
Proceeds from issuance of common stock | 11 | 2 | 9 | 34 | 8 | (57 | ) | (42 | ) | |||||||||||||||||||||||||
Decrease in funds held by trustee | (0 | ) | (0 | ) | (1 | ) | 0 | (4 | ) | (0 | ) | 1 | ||||||||||||||||||||||
Net cash provided by (used in) financing activities | 7 | (11 | ) | 2 | 14 | 40 | 175 | 16 | ||||||||||||||||||||||||||
Increase (Decrease) in cash and cash equivalents | 35 | (34 | ) | (44 | ) | 36 | (55 | ) | 0 | 10 | ||||||||||||||||||||||||
Cash and cash equivalents, Beginning of Period | 74 | 109 | 75 | 31 | 67 | 13 | 13 | |||||||||||||||||||||||||||
Cash and cash equivalents, End of Period | 109 | 75 | 31 | 67 | 13 | 13 | 23 |
Page 53
Health Management Associates
Balance Sheet
($ in thousands, except per share) | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||||||||||
Current Assets: | |||||||||||||||||||||||||||||||||||
Cash and cash equivalents | 109 | 75 | 31 | 67 | 13 | 13 | 23 | ||||||||||||||||||||||||||||
Accounts receivable, net | 55 | 69 | 103 | 119 | 219 | 312 | 342 | ||||||||||||||||||||||||||||
Funds held by trustee | 1 | 1 | 2 | 1 | 1 | 2 | 0 | ||||||||||||||||||||||||||||
Income taxes-receivable and deferred | 2 | 7 | 12 | 13 | 18 | 31 | 0 | ||||||||||||||||||||||||||||
Other current assets | 9 | 22 | 29 | 35 | 57 | 68 | 122 | ||||||||||||||||||||||||||||
Total current assets | 178 | 175 | 178 | 236 | 309 | 425 | 488 | ||||||||||||||||||||||||||||
Property and equipment | 279 | 365 | 505 | 473 | 926 | 1,142 | 1,088 | ||||||||||||||||||||||||||||
Less: accumulated depreciation | (65 | ) | (82 | ) | (107 | ) | 0 | (188 | ) | (230 | ) | (21 | ) | ||||||||||||||||||||||
Net property and equipment | 214 | 283 | 398 | 473 | 738 | 912 | 1,068 | ||||||||||||||||||||||||||||
Other assets: | |||||||||||||||||||||||||||||||||||
Funds held by trustee | 0 | 0 | 0 | 1 | 4 | 4 | 3 | ||||||||||||||||||||||||||||
Deferred charges and other assets | 7 | 10 | 16 | 18 | 62 | 175 | 184 | ||||||||||||||||||||||||||||
Total Assets | 399 | 468 | 592 | 728 | 1,112 | 1,517 | 1,742 | ||||||||||||||||||||||||||||
Liabilities and Stockholders Equity | |||||||||||||||||||||||||||||||||||
Current liabilities: | |||||||||||||||||||||||||||||||||||
Accounts payable | 15 | 22 | 29 | 34 | 44 | 74 | 93 | ||||||||||||||||||||||||||||
Accrued expenses and other liabilities | 17 | 23 | 30 | 37 | 58 | 72 | 73 | ||||||||||||||||||||||||||||
Income taxes currently payable and deferred | 0 | 0 | 4 | 3 | 10 | 20 | 0 | ||||||||||||||||||||||||||||
Current maturities of long term debt | 7 | 7 | 8 | 8 | 9 | 9 | 0 | ||||||||||||||||||||||||||||
Total current liabilities | 40 | 51 | 71 | 83 | 121 | 175 | 166 | ||||||||||||||||||||||||||||
Deferred income taxes | 19 | 18 | 19 | 19 | 40 | 33 | 33 | ||||||||||||||||||||||||||||
Other long term liabilities | 11 | 12 | 15 | 16 | 61 | 17 | 18 | ||||||||||||||||||||||||||||
Long term debt, net of current maturities | 76 | 68 | 69 | 50 | 134 | 402 | 499 | ||||||||||||||||||||||||||||
Common stockholders equity: | |||||||||||||||||||||||||||||||||||
Preferred stock, $0.01 par value, 5,000,000 | |||||||||||||||||||||||||||||||||||
Common Stock, Class A, $0.01 par value | 0 | 1 | 1 | 0 | 2 | 3 | 0 | ||||||||||||||||||||||||||||
Additional paid in capital | 132 | 134 | 149 | 0 | 242 | 295 | 0 | ||||||||||||||||||||||||||||
Treasury stock | |||||||||||||||||||||||||||||||||||
Retained earnings | 120 | 183 | 267 | 560 | 513 | 663 | 1,027 | ||||||||||||||||||||||||||||
Total stockholders equity | 253 | 318 | 418 | 560 | 757 | 891 | 1,027 | ||||||||||||||||||||||||||||
Total Assets and Shareholders Equity | 399 | 467 | 592 | 728 | 1,112 | 1,517 | 1,742 |
Page 54
1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||||||||||||
ROA - Operations | 14.6 | % | 15.9 | % | 16.4 | % | 14.9 | % | 11.4 | % | 10.3 | % | ||||||||||||||||||||||||
ROC - Operations | 17.7 | % | 19.3 | % | 19.8 | % | 18.2 | % | 13.7 | % | 12.0 | % | ||||||||||||||||||||||||
ROE - Operations | 22.2 | % | 22.9 | % | 22.2 | % | 20.8 | % | 18.2 | % | 17.6 | % | ||||||||||||||||||||||||
ROA - Total | 14.6 | % | 15.9 | % | 16.4 | % | 14.9 | % | 11.4 | % | 10.3 | % | ||||||||||||||||||||||||
ROC - Total | 17.7 | % | 19.3 | % | 19.8 | % | 16.2 | % | 13.7 | % | 12.0 | % | ||||||||||||||||||||||||
ROE - Total | 22.2 | % | 22.9 | % | 22.2 | % | 20.8 | % | 18.2 | % | 17.6 | % | ||||||||||||||||||||||||
LTD: Equity | 0.30 | 0.21 | 0.16 | 0.09 | 0.18 | 0.45 | 0.49 | |||||||||||||||||||||||||||||
Total Debt: Equity | 0.33 | 0.23 | 0.18 | 0.10 | 0.19 | 0.46 | 0.49 | |||||||||||||||||||||||||||||
Total Debt: EBITDA | 0.81 | 0.58 | 0.46 | 0.26 | 0.51 | 1.30 | 1.31 | |||||||||||||||||||||||||||||
Interest Coverage | 23.02 | 35.47 | 46.11 | 58.89 | 58.94 | 37.72 | 14.20 | |||||||||||||||||||||||||||||
Cost of Debt Capital | 4.6 | % | 4.6 | % | 5.5 | % | 4.7 | % | 3.0 | % | 5.9 | % | ||||||||||||||||||||||||
EBITDA / Share | $ | 0.44 | $ | 0.54 | $ | 0.69 | $ | 0.88 | $ | 1.10 | $ | 1.26 | $ | 1.57 | ||||||||||||||||||||||
EBITDA / Share Growth | 23.2 | % | 29.2 | % | 26.6 | % | 25.1 | % | 15.1 | % | 24.7 | % | ||||||||||||||||||||||||
EBITDA Margin | 23.5 | % | 24.2 | % | 23.7 | % | 24.4 | % | 24.6 | % | 23.3 | % | 23.5 | % | ||||||||||||||||||||||
D&A % Revenue | 3.8 | % | 3.8 | % | 3.8 | % | 4.1 | % | 4.4 | % | 4.5 | % | 4.7 | % | ||||||||||||||||||||||
EBIT Margin | 19.7 | % | 20.3 | % | 19.9 | % | 20.3 | % | 20.2 | % | 18.8 | % | 18.8 | % | ||||||||||||||||||||||
Interest % Revenue | 1.0 | % | 0.7 | % | 0.5 | % | 0.4 | % | 0.4 | % | 0.6 | % | 1.7 | % | ||||||||||||||||||||||
Pretax Margin | 18.6 | % | 19.6 | % | 19.4 | % | 19.9 | % | 19.8 | % | 18.2 | % | 17.1 | % | ||||||||||||||||||||||
Revenue Growth | 21.2 | % | 34.5 | % | 25.4 | % | 27.2 | % | 19.0 | % | 19.5 | % | ||||||||||||||||||||||||
EBITDA Growth | 24.9 | % | 31.7 | % | 29.3 | % | 28.3 | % | 12.8 | % | 20.4 | % | ||||||||||||||||||||||||
EPS Growth | 34.2 | % | 30.3 | % | 26.2 | % | 23.1 | % | 11.7 | % | 14.8 | % | ||||||||||||||||||||||||
Capital Expenditures: Depreciation | 1.36 | 1.12 | 1.52 | 1.62 | 1.07 | 2.60 | 1.47 | |||||||||||||||||||||||||||||
Employees | 10,000 | 15,000 | 16,000 | 18,000 | ||||||||||||||||||||||||||||||||
Regional / Divisional / Home Office Empl | 55 | 55 | 65 | |||||||||||||||||||||||||||||||||
Revenue / Employee | 90 | 76 | 85 | 90 | ||||||||||||||||||||||||||||||||
EBITDA / Employee | 22 | 19 | 20 | 21 | ||||||||||||||||||||||||||||||||
Cash Flow Operations / Revenues | 10.5 | % | 14.0 | % | 13.2 | % | 14.8 | % | 11.2 | % | 12.4 | % | 10.3 | % | ||||||||||||||||||||||
Cash Flow Operations - Cap Ex / Revenues | 5.4 | % | 9.7 | % | 7.5 | % | 8.2 | % | 6.4 | % | 0.7 | % | 3.4 | % | ||||||||||||||||||||||
Stock Price 9/30 | 3.480 | 4.863 | 6.344 | 11.109 | 14.055 | 18.250 | 7.750 | 14.500 | ||||||||||||||||||||||||||||
Stockholder Annual Return | 39.7 | % | 30.4 | % | 75.1 | % | 26.5 | % | 29.8 | % | -57.5 | % | 87.1 | % | ||||||||||||||||||||||
3 Year Return | 219.2 | % | 189.0 | % | 167.7 | % | -30.2 | % | 3.2 | % | ||||||||||||||||||||||||||
4 Year Return | 303.8 | % | 275.3 | % | 22.2 | % | 30.5 | % | ||||||||||||||||||||||||||||
5 Year Return | 424.4 | % | 59.4 | % | 128.6 | % | ||||||||||||||||||||||||||||||
Net A/R DSO | 46.1 | 47.3 | 52.7 | 48.6 | 70.2 | 84.0 | 77.2 | |||||||||||||||||||||||||||||
Change from Last Year | 1.2 | 5.3 | (4.0 | ) | 21.6 | 13.8 | (6.8 | ) | ||||||||||||||||||||||||||||
Change from 3 Years Ago | 2.5 | 22.9 | 31.3 | 28.5 | ||||||||||||||||||||||||||||||||
Cash Cost of 3 Year Change | 116 | 126 |
Page 55
Quorum Health Group
1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | |||||||||||||||||||||||||||
Net patient service revenue | 520 | 724 | 963 | 1,274 | 1,428 | 1,505 | 1,614 | |||||||||||||||||||||||||||
Hospital management | 73 | 74 | 78 | 79 | 80 | 83 | 80 | |||||||||||||||||||||||||||
Reimbursable expenses | 48 | 52 | 57 | 61 | 65 | 65 | 64 | |||||||||||||||||||||||||||
Net operating revenue | 343 | 641 | 850 | 1,099 | 1,414 | 1,572 | 1,653 | 1,758 | ||||||||||||||||||||||||||
Salaries and benefits | 130 | 235 | 320 | 421 | 561 | 628 | 687 | 722 | ||||||||||||||||||||||||||
Reimbursable expenses | 43 | 48 | 52 | 57 | 61 | 65 | 65 | 64 | ||||||||||||||||||||||||||
Supplies | 41 | 90 | 122 | 161 | 198 | 210 | 231 | 255 | ||||||||||||||||||||||||||
Fees | 29 | 56 | 83 | 103 | 126 | 141 | 157 | 158 | ||||||||||||||||||||||||||
Other operating | 29 | 57 | 68 | 93 | 117 | 130 | 122 | 129 | ||||||||||||||||||||||||||
Doubtful accounts | 16 | 39 | 49 | 56 | 90 | 107 | 127 | 130 | ||||||||||||||||||||||||||
Equity in earnings of affiliates | 0 | 0 | 0 | 0 | 0 | 7 | 22 | 19 | ||||||||||||||||||||||||||
EBITDAR | 56 | 116 | 156 | 208 | 261 | 299 | 252 | 319 | ||||||||||||||||||||||||||
Leases and rentals | 0 | 0 | 0 | 0 | 0 | 0 | 34 | 37 | ||||||||||||||||||||||||||
EBITDA | 56 | 116 | 156 | 208 | 261 | 299 | 252 | 282 | ||||||||||||||||||||||||||
Depreciation /amortization | 15 | 28 | 38 | 56 | 75 | 87 | 95 | 108 | ||||||||||||||||||||||||||
EBIT | 41 | 88 | 119 | 152 | 186 | 212 | 157 | 211 | ||||||||||||||||||||||||||
Interest | 14 | 25 | 22 | 37 | 46 | 41 | 54 | 69 | ||||||||||||||||||||||||||
Loss (gain) on sale of assets | 0 | 0 | 0 | (1 | ) | 0 | 0 | 35 | 0 | |||||||||||||||||||||||||
Minority interest | 1 | 1 | 1 | 0 | 1 | 3 | (6 | ) | 4 | |||||||||||||||||||||||||
Income before taxes & extraordinary | 26 | 62 | 95 | 117 | 139 | 168 | 72 | 95 | ||||||||||||||||||||||||||
Income taxes | 10 | 26 | 40 | 47 | 55 | 67 | 33 | 37 | ||||||||||||||||||||||||||
Income before extraordinary items | 16 | 36 | 56 | 69 | 84 | 102 | 39 | 58 | ||||||||||||||||||||||||||
Extraordinary item | 0 | 0 | 0 | 0 | (8 | ) | (15 | ) | 0 | 0 | ||||||||||||||||||||||||
Net income | 0 | 0 | 0 | 0 | 76 | 87 | 39 | 58 | ||||||||||||||||||||||||||
EPS: | ||||||||||||||||||||||||||||||||||
Primary (operating) | $ | 0.27 | $ | 0.64 | $ | 0.76 | $ | 0.93 | $ | 1.11 | $ | 1.36 | $ | 0.53 | $ | 0.81 | ||||||||||||||||||
Extraordinary item | $ | | $ | | $ | | $ | | $ | | $ | (0.20 | ) | $ | | $ | | |||||||||||||||||
Net earnings per share | $ | | $ | | $ | | $ | | $ | 1.00 | $ | 1.16 | $ | 0.53 | $ | 0.81 | ||||||||||||||||||
Fully Diluted (operating) | $ | 0.25 | $ | 0.59 | $ | 0.76 | $ | 0.93 | $ | 1.11 | $ | 1.32 | $ | 0.52 | $ | 0.75 | ||||||||||||||||||
Extraordinary item | $ | | $ | | $ | | $ | | $ | | $ | (0.19 | ) | $ | | $ | | |||||||||||||||||
Net earnings per share | $ | | $ | | $ | | $ | | $ | 1.00 | $ | 1.12 | $ | 0.52 | $ | 0.75 | ||||||||||||||||||
Average shares: | ||||||||||||||||||||||||||||||||||
Primary | 59.4 | 56.7 | 73.7 | 74.6 | 75.9 | 74.7 | 73.5 | 71.5 | ||||||||||||||||||||||||||
Fully Diluted | 66.8 | 61.8 | 73.7 | 74.6 | 76.0 | 77.2 | 74.4 | 82.0 |
Page 56
Margin Assumptions | ||||||||||||||||||||||||||||||||
Salaries/Revs | 37.8 | % | 36.7 | % | 37.6 | % | 38.3 | % | 39.7 | % | 39.9 | % | 41.6 | % | 41.1 | % | ||||||||||||||||
Reimb Exp/Revs | 12.4 | % | 7.5 | % | 6.1 | % | 5.2 | % | 4.3 | % | 4.1 | % | 3.9 | % | 3.6 | % | ||||||||||||||||
Supplies/Revs | 11.9 | % | 14.0 | % | 14.3 | % | 14.6 | % | 14.0 | % | 13.4 | % | 14.0 | % | 14.5 | % | ||||||||||||||||
Fees/Revs | 8.3 | % | 8.7 | % | 9.8 | % | 9.3 | % | 8.9 | % | 9.0 | % | 9.5 | % | 9.0 | % | ||||||||||||||||
Other Operating | 8.3 | % | 8.9 | % | 8.0 | % | 8.4 | % | 8.3 | % | 8.2 | % | 7.4 | % | 7.3 | % | ||||||||||||||||
Doubtful Accounts | 4.8 | % | 6.1 | % | 5.7 | % | 5.1 | % | 6.4 | % | 6.8 | % | 7.7 | % | 7.4 | % | ||||||||||||||||
EBITDA Margin | 16.4 | % | 18.1 | % | 18.4 | % | 19.0 | % | 18.5 | % | 19.0 | % | 15.3 | % | 18.2 | % | ||||||||||||||||
EBITDA Margin excluding reimbursement | 18.7 | % | 19.6 | % | 19.6 | % | 20.0 | % | 19.3 | % | 19.8 | % | 15.9 | % | 18.8 | % | ||||||||||||||||
EBITDA Margin excluding JV equity | 18.7 | % | 19.6 | % | 19.6 | % | 20.0 | % | 19.3 | % | 19.4 | % | 14.5 | % | 17.7 | % | ||||||||||||||||
Depreciation % PPE | 0.0 | % | 0.0 | % | 0.0 | % | 0.0 | % | 0.0 | % | 0.0 | % | 0.0 | % | 0.0 | % | ||||||||||||||||
Tax Rate | 39.6 | % | 41.4 | % | 41.4 | % | 40.6 | % | 39.7 | % | 39.7 | % | 46.3 | % | 39.1 | % |
Page 57
Quorum Health Group
Cash Flow Statement
($ in thousands, except per share) | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | ||||||||||||||||||||||||||
Cash Flow From Operations | ||||||||||||||||||||||||||||||||||
Net income | 36 | 56 | 69 | 76 | 87 | 39 | 58 | |||||||||||||||||||||||||||
Depreciation | 24 | 38 | 57 | 75 | 87 | 95 | 108 | |||||||||||||||||||||||||||
Minority Interest | 1 | 1 | 1 | 1 | 3 | (16 | ) | 4 | ||||||||||||||||||||||||||
Other operating | 10 | (7 | ) | (13 | ) | 15 | (52 | ) | 11 | (5 | ) | |||||||||||||||||||||||
Cash Flow From Operations | 72 | 88 | 114 | 167 | 125 | 129 | 164 | |||||||||||||||||||||||||||
Cash Flow From Investing | ||||||||||||||||||||||||||||||||||
Acquisition | (350 | ) | (100 | ) | (205 | ) | (176 | ) | (132 | ) | (217 | ) | (20 | ) | ||||||||||||||||||||
PP&E | (36 | ) | (58 | ) | (62 | ) | (71 | ) | (132 | ) | (124 | ) | (104 | ) | ||||||||||||||||||||
Assets held for sale | (37 | ) | 3 | 0 | 0 | 0 | 13 | 7 | ||||||||||||||||||||||||||
Assets sold | 67 | 4 | 1 | 0 | 15 | 0 | 0 | |||||||||||||||||||||||||||
Other | (1 | ) | 0 | 0 | 2 | (4 | ) | (1 | ) | 1 | ||||||||||||||||||||||||
Cash Flow From Investing | (357 | ) | (151 | ) | (266 | ) | (245 | ) | (253 | ) | (329 | ) | (116 | ) | ||||||||||||||||||||
Cash Flow From Financing | ||||||||||||||||||||||||||||||||||
Principal payments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Proceeds from notes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Proceeds from issuance of senior notes | 0 | 0 | 150 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Borrowing under credit line | 381 | 269 | 364 | 351 | 96 | 256 | (189 | ) | ||||||||||||||||||||||||||
Payments under credit line | (269 | ) | (212 | ) | (368 | ) | (179 | ) | 0 | 0 | 0 | |||||||||||||||||||||||
Common stock | 166 | 6 | 6 | 8 | 13 | (39 | ) | (13 | ) | |||||||||||||||||||||||||
Subordinated notes | (18 | ) | 0 | 0 | (100 | ) | 0 | 0 | 150 | |||||||||||||||||||||||||
Loan origination costs | (1 | ) | (2 | ) | (5 | ) | (0 | ) | 0 | 0 | 0 | |||||||||||||||||||||||
Other | (1 | ) | (1 | ) | (2 | ) | (2 | ) | 17 | (12 | ) | (4 | ) | |||||||||||||||||||||
Cash Flow From Financing | 258 | 60 | 145 | 77 | 127 | 205 | (57 | ) | ||||||||||||||||||||||||||
Net Cash Flow | (26 | ) | (3 | ) | (7 | ) | (1 | ) | (1 | ) | 5 | (9 | ) | |||||||||||||||||||||
Beginning cash | 57 | 30 | 27 | 20 | 19 | 18 | 22 | |||||||||||||||||||||||||||
Ending cash | 30 | 27 | 20 | 19 | 18 | 22 | 13 |
Page 58
Quorum Health Group
Balance Sheet
($ in thousands, except per share) | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | ||||||||||||||||||||||||||
Assets | ||||||||||||||||||||||||||||||||||
Current Assets | ||||||||||||||||||||||||||||||||||
Cash and equivalents | 30 | 27 | 20 | 19 | 18 | 22 | 13 | |||||||||||||||||||||||||||
Accounts receivable | 107 | 145 | 186 | 249 | 273 | 332 | 337 | |||||||||||||||||||||||||||
Supplies | 17 | 21 | 27 | 32 | 29 | 39 | 36 | |||||||||||||||||||||||||||
Deferred income taxes | 7 | 7 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Assets for sale | 6 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Other current assets | 15 | 18 | 26 | 32 | 34 | 47 | 53 | |||||||||||||||||||||||||||
Total current assets | 183 | 218 | 259 | 331 | 355 | 440 | 439 | |||||||||||||||||||||||||||
PP&E, net | 314 | 419 | 551 | 687 | 679 | 835 | 851 | |||||||||||||||||||||||||||
Goodwill | 111 | 111 | 143 | 186 | 144 | 226 | 225 | |||||||||||||||||||||||||||
Other assets | 18 | 25 | 68 | 75 | 313 | 330 | 331 | |||||||||||||||||||||||||||
626 | 774 | 1,021 | 1,279 | 1,491 | 1,832 | 1,845 | ||||||||||||||||||||||||||||
Liabilities and Shareholders Equity | ||||||||||||||||||||||||||||||||||
Current Liabilities | ||||||||||||||||||||||||||||||||||
Accounts payable | 32 | 39 | 47 | 77 | 70 | 97 | 101 | |||||||||||||||||||||||||||
Accrued salaries | 26 | 36 | 43 | 62 | 64 | 73 | 72 | |||||||||||||||||||||||||||
Accrued pension | 6 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Accrued taxes | 4 | 2 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Deferred income | 6 | 6 | 5 | 6 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Other current liabilities | 3 | 1 | 2 | 3 | 28 | 35 | 31 | |||||||||||||||||||||||||||
Current LTD | 5 | 2 | 2 | 2 | 1 | 1 | 1 | |||||||||||||||||||||||||||
Current Liabilities | 81 | 85 | 99 | 151 | 163 | 205 | 206 | |||||||||||||||||||||||||||
LTD | 225 | 287 | 431 | 520 | 617 | 872 | 832 | |||||||||||||||||||||||||||
Reserves for liability | 7 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Deferred taxes | 11 | 24 | 33 | 38 | 29 | 33 | 28 | |||||||||||||||||||||||||||
Other liabilities | 4 | 15 | 20 | 25 | 31 | 36 | 43 | |||||||||||||||||||||||||||
Minority interest | 4 | 6 | 6 | 27 | 27 | 60 | 66 | |||||||||||||||||||||||||||
Common Equity | 294 | 356 | 432 | 518 | 622 | 625 | 670 | |||||||||||||||||||||||||||
626 | 774 | 1,021 | 1,279 | 1,491 | 1,832 | 1,845 |
Page 59
1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||||||||
ROA - Operations | 3.2% | 4.1% | 4.0% | 2.9% | 3.2% | 3.8% | ||||||||||||||||||||||||||
ROC - Operations | 3.8% | 4.9% | 4.8% | 3.6% | 3.9% | 4.6% | ||||||||||||||||||||||||||
ROE - Operations | 6.8% | 9.3% | 9.6% | 7.1% | 8.6% | 10.7% | ||||||||||||||||||||||||||
ROA-Total | 3.2% | 4.1% | 4.0% | 2.9% | 3.2% | 3.8% | ||||||||||||||||||||||||||
ROC-Total | 3.8% | 4.9% | 4.8% | 3.6% | 3.9% | 4.6% | ||||||||||||||||||||||||||
ROE-Total | 6.8% | 9.3% | 9.6% | 7.1% | 8.6% | 10.7% | ||||||||||||||||||||||||||
LTD : Equity | 0.77 | 0.81 | 1.00 | 1.00 | 0.99 | 1.40 | 1.24 | |||||||||||||||||||||||||
Total Debt : Equity | 0.78 | 0.81 | 1.00 | 1.01 | 0.99 | 1.40 | 1.24 | |||||||||||||||||||||||||
Total Debt : EBITDA | 1.98 | 1.85 | 2.08 | 2.00 | 2.07 | 3.46 | 2.95 | |||||||||||||||||||||||||
Interest Coverage | 4.63 | 7.04 | 5.70 | 5.72 | 7.37 | 4.70 | 4.08 | |||||||||||||||||||||||||
Cost of Debt Capital | 8.6% | 10.1% | 9.5% | 7.1% | 7.2% | 8.1% | ||||||||||||||||||||||||||
EBITDA / Share | $ | 2.05 | $ | 2.12 | $ | 2.79 | $ | 3.44 | $ | 4.00 | $ | 3.43 | $ | 3.95 | ||||||||||||||||||
EBITDA / Share Growth | 3.5% | 31.7% | 23.1% | 16.5% | -14.3% | 15.1% | ||||||||||||||||||||||||||
EBITDA Margin | 18.1% | 18.4% | 19.0% | 18.5% | 19.0% | 15.3% | 16.1% | |||||||||||||||||||||||||
D&A % Revenue | 4.4% | 4.4% | 5.1% | 5.3% | 5.5% | 5.8% | 6.1% | |||||||||||||||||||||||||
EBIT Margin | 13.7% | 14.0% | 13.9% | 13.1% | 13.6% | 9.5% | 12.0% | |||||||||||||||||||||||||
Interest % Revenue | 3.9% | 2.6% | 3.3% | 3.2% | 2.6% | 3.2% | 3.9% | |||||||||||||||||||||||||
Pretax Margin | 9.6% | 11.2% | 10.6% | 9.9% | 10.7% | 4.4% | 5.4% | |||||||||||||||||||||||||
Revenue Growth | 86.8% | 32.6% | 29.2% | 28.7% | 11.2% | 5.1% | 6.4% | |||||||||||||||||||||||||
EBITDA Growth | 106.3% | 34.7% | 33.3% | 25.2% | 14.6% | -15.7% | 12.0% | |||||||||||||||||||||||||
EPS Growth | 137.7% | 29.4% | 22.2% | 19.3% | 18.9% | -60.3% | 43.9% | |||||||||||||||||||||||||
Capital Expenditures : Depreciation | 1.28 | 1.55 | 1.11 | 0.95 | 1.51 | 1.30 | 0.96 | |||||||||||||||||||||||||
Employees | 17,935 | 18,890 | 20,900 | 20,900 | ||||||||||||||||||||||||||||
Regional / Divisional / Home Office Empl | 118 | 130 | 150 | |||||||||||||||||||||||||||||
Revenue / Employee | 79 | 83 | 79 | 84 | ||||||||||||||||||||||||||||
EBITDA / Employee | 15 | 16 | 12 | 14 | ||||||||||||||||||||||||||||
Cash Flow Operations / Revenues | 11.2% | 10.4% | 10.4% | 11.8% | 7.9% | 7.8% | 9.3% | |||||||||||||||||||||||||
Cash Flow Operations-Cap Ex / Revenues | 5.6% | 3.5% | 4.7% | 6.8% | -0.4% | 0.3% | 3.4% | |||||||||||||||||||||||||
Stock Price 6/30 | 11.668 | 13.500 | 17.582 | 23.832 | 26.500 | 12.563 | 10.313 | |||||||||||||||||||||||||
Stockholder Annual Return | 15.7% | 30.2% | 35.5% | 11.2% | -52.6% | -17.9% | ||||||||||||||||||||||||||
3 Year Return | 104.3% | 96.3% | -28.5% | -56.7% | ||||||||||||||||||||||||||||
4 Year Return | 127.1% | -6.9% | -41.3% | |||||||||||||||||||||||||||||
5 Year Return | 7.7% | -23.6% | ||||||||||||||||||||||||||||||
Net A/R DSO | 61.1 | 62.2 | 61.7 | 64.2 | 63.5 | 73.4 | 69.9 | |||||||||||||||||||||||||
Change from Last Year | 1.0 | (0.4 | ) | 2.5 | (0.7 | ) | 9.9 | (3.5 | ) | |||||||||||||||||||||||
Change from 3 Years Ago | 3.1 | 1.3 | 11.7 | 5.7 | ||||||||||||||||||||||||||||
Cash Cost of 3 year Change | 53 | 28 |
Page 60
Matrix of Financial Indicators
Return on Assets
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 2.8 | % | 4.3 | % | -2.4 | % | 2.1 | % | 1.9 | % | 2.2 | % | ||||||||||||
HCA | 6.6 | % | 7.3 | % | -1.4 | % | 1.8 | % | 3.6 | % | 2.3 | % | ||||||||||||
UHS | 5.6 | % | 5.9 | % | 6.6 | % | 6.3 | % | 5.3 | % | 5.5 | % | ||||||||||||
HMA | 14.6 | % | 15.9 | % | 16.4 | % | 14.9 | % | 11.4 | % | 10.3 | % | ||||||||||||
QHGI | 3.2 | % | 4.1 | % | 4.0 | % | 2.9 | % | 3.2 | % | 3.8 | % | ||||||||||||
Competitor Average | 7.5 | % | 8.3 | % | 6.4 | % | 6.5 | % | 5.9 | % | 5.5 | % |
Return on Capital
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 4.9 | % | 6.3 | % | -3.5 | % | 3.0 | % | 2.5 | % | 3.0 | % | ||||||||||||
HCA | 9.2 | % | 10.1 | % | -1.9 | % | 2.5 | % | 5.4 | % | 3.4 | % | ||||||||||||
UHS | 8.1 | % | 8.0 | % | 8.8 | % | 8.6 | % | 7.4 | % | 7.6 | % | ||||||||||||
HMA | 17.7 | % | 19.3 | % | 19.8 | % | 18.2 | % | 13.7 | % | 12.0 | % | ||||||||||||
QHGI | 3.8 | % | 4.9 | % | 4.8 | % | 3.6 | % | 3.9 | % | 4.6 | % | ||||||||||||
Competitor Average | 9.7 | % | 10.6 | % | 7.9 | % | 8.2 | % | 7.6 | % | 6.9 | % |
Return on Equity
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 10.0 | % | 15.1 | % | -8.3 | % | 7.7 | % | 6.7 | % | 7.6 | % | ||||||||||||
HCA | 17.5 | % | 19.1 | % | -3.8 | % | 5.1 | % | 10.0 | % | 6.8 | % | ||||||||||||
UHS | 12.7 | % | 13.5 | % | 13.7 | % | 13.8 | % | 12.3 | % | 13.1 | % | ||||||||||||
HMA | 22.2 | % | 22.9 | % | 22.2 | % | 20.8 | % | 18.2 | % | 17.6 | % | ||||||||||||
QHGI | 6.8 | % | 9.3 | % | 9.6 | % | 7.1 | % | 8.6 | % | 10.7 | % | ||||||||||||
Competitor Average | 14.8 | % | 16.2 | % | 10.4 | % | 11.7 | % | 12.3 | % | 12.1 | % |
Page 61
Matrix of Financial Indicators
LTD: Equity
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 1.65x | 1.21x | 1.56x | 1.64x | 1.65x | 1.39x | ||||||||||||||||||
HCA | 1.00x | 0.79x | 1.28x | 0.75x | 0.94x | 1.01x | ||||||||||||||||||
UHS | 0.80x | 0.61x | 0.52x | 0.67x | 0.65x | 0.77x | ||||||||||||||||||
HMA | 0.21x | 0.16x | 0.09x | 0.18x | 0.45x | 0.49x | ||||||||||||||||||
QHGI | 0.81x | 1.00x | 1.00x | 0.99x | 1.40x | 1.24x | ||||||||||||||||||
Competitor Average | 0.70x | 0.64x | 0.72x | 0.65x | 0.86x | 0.88x |
Total Debt : Equity
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 1.79x | 1.23x | 1.57x | 1.64x | 1.66x | 1.40x | ||||||||||||||||||
HCA | 1.04x | 0.81x | 1.30x | 0.89x | 1.15x | 1.13x | ||||||||||||||||||
UHS | 0.82x | 0.62x | 0.53x | 0.67x | 0.66x | 0.77x | ||||||||||||||||||
HMA | 0.23x | 0.18x | 0.10x | 0.19x | 0.46x | 0.49x | ||||||||||||||||||
QHGI | 0.81x | 1.00x | 1.01x | 0.99x | 1.40x | 1.24x | ||||||||||||||||||
Competitor Average | 0.72x | 0.66x | 0.73x | 0.69x | 0.92x | 0.91x |
Total Debt: EBITDA
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 5.71x | 2.96x | 3.31x | 3.23x | 3.464x | 2.93x | ||||||||||||||||||
HCA | 1.98x | 1.62x | 3.30x | 2.35x | 2.23x | 2.06x | ||||||||||||||||||
UHS | 2.11x | 1.63x | 1.35x | 1.60x | 1.60x | 1.95x | ||||||||||||||||||
HMA | 0.58x | 0.46x | 0.26x | 0.51x | 1.30x | 1.31x | ||||||||||||||||||
QHGI | 1.85x | 2.08x | 2.00x | 2.07x | 3.463x | 2.95x | ||||||||||||||||||
Competitor Average | 1.63x | 1.45x | 1.73x | 1.63x | 2.15x | 2.07x |
Page 62
Matrix of Financial Indicators
EBITDA: Interest
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 4.51x | 3.52x | 3.65x | 3.90x | 3.83x | 4.04x | ||||||||||||||||||
HCA | 8.09x | 8.65x | 5.78x | 5.11x | 6.13x | 6.13x | ||||||||||||||||||
UHS | 10.32x | 8.15x | 10.63x | 9.76x | 9.83x | 8.92x | ||||||||||||||||||
HMA | 35.47x | 48.11x | 58.89x | 58.94x | 37.72x | 14.20x | ||||||||||||||||||
QHGI | 7.04x | 5.70x | 5.72x | 7.37x | 4.70x | 4.08x | ||||||||||||||||||
Competitor Average | 15.23x | 17.65x | 20.25x | 20.29x | 14.60x | 8.33x |
Average Cost of Debt
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 6.43 | % | 9.21 | % | 10.05 | % | 8.52 | % | 7.90 | % | 7.91 | % | ||||||||||||
HCA | 8.13 | % | 6.93 | % | 6.02 | % | 6.94 | % | 7.14 | % | 7.94 | % | ||||||||||||
UHS | 6.65 | % | 8.07 | % | 6.91 | % | 7.74 | % | 6.36 | % | 6.52 | % | ||||||||||||
HMA | 4.61 | % | 4.64 | % | 5.50 | % | 4.74 | % | 3.03 | % | 5.90 | % | ||||||||||||
QHGI | 8.55 | % | 10.13 | % | 9.55 | % | 7.12 | % | 7.20 | % | 8.10 | % | ||||||||||||
Competitor Average | 6.99 | % | 7.44 | % | 6.99 | % | 6.64 | % | 5.93 | % | 7.12 | % |
EBITDA Margin
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 18.8 | % | 19.8 | % | 17.5 | % | 18.3 | % | 17.1 | % | 17.0 | % | ||||||||||||
HCA | 21.0 | % | 21.6 | % | 15.1 | % | 15.4 | % | 17.3 | % | 19.0 | % | ||||||||||||
UHS | 12.4 | % | 14.6 | % | 14.3 | % | 14.1 | % | 12.9 | % | 13.3 | % | ||||||||||||
HMA | 24.2 | % | 23.7 | % | 24.4 | % | 24.6 | % | 23.3 | % | 23.5 | % | ||||||||||||
QHGI | 18.4 | % | 19.0 | % | 18.5 | % | 19.0 | % | 15.3 | % | 16.1 | % | ||||||||||||
Competitor Average | 19.0 | % | 19.7 | % | 18.1 | % | 18.3 | % | 17.2 | % | 18.0 | % |
Page 63
Matrix of Financial Indicators
D&A % of Revenue
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 5.9 | % | 5.8 | % | 5.1 | % | 4.6 | % | 5.1 | % | 4.7 | % | ||||||||||||
HCA | 5.5 | % | 5.8 | % | 6.6 | % | 6.7 | % | 6.6 | % | 6.2 | % | ||||||||||||
UHS | 5.5 | % | 6.0 | % | 5.6 | % | 5.6 | % | 5.3 | % | 4.8 | % | ||||||||||||
HMA | 3.9 | % | 3.8 | % | 4.1 | % | 4.4 | % | 4.5 | % | 4.7 | % | ||||||||||||
QHGI | 4.4 | % | 5.1 | % | 5.3 | % | 5.5 | % | 5.8 | % | 6.1 | % | ||||||||||||
Competitor Average | 4.8 | % | 5.2 | % | 5.4 | % | 5.6 | % | 5.5 | % | 5.5 | % |
EBIT Margin
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 12.9 | % | 14.0 | % | 12.4 | % | 13.6 | % | 12.0 | % | 12.3 | % | ||||||||||||
HCA | 15.5 | % | 15.8 | % | 8.6 | % | 8.7 | % | 10.8 | % | 12.8 | % | ||||||||||||
UHS | 6.9 | % | 8.5 | % | 8.7 | % | 8.5 | % | 7.6 | % | 8.6 | % | ||||||||||||
HMA | 20.3 | % | 19.9 | % | 20.3 | % | 20.2 | % | 18.8 | % | 18.8 | % | ||||||||||||
QHGI | 14.0 | % | 13.9 | % | 13.1 | % | 13.5 | % | 9.5 | % | 12.0 | % | ||||||||||||
Competitor Average | 14.2 | % | 14.5 | % | 12.7 | % | 12.7 | % | 11.7 | % | 13.1 | % |
Interest % of Revenue
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 4.2 | % | 5.6 | % | 4.8 | % | 4.7 | % | 4.5 | % | 4.2 | % | ||||||||||||
HCA | 2.6 | % | 2.5 | % | 2.6 | % | 3.0 | % | 2.8 | % | 3.1 | % | ||||||||||||
UHS | 1.2 | % | 1.8 | % | 1.3 | % | 1.4 | % | 1.3 | % | 1.5 | % | ||||||||||||
HMA | 0.7 | % | 0.5 | % | 0.4 | % | 0.4 | % | 0.6 | % | 1.7 | % | ||||||||||||
QHGI | 2.6 | % | 3.3 | % | 3.2 | % | 2.6 | % | 3.2 | % | 3.9 | % | ||||||||||||
Competitor Average | 1.8 | % | 2.0 | % | 1.9 | % | 1.9 | % | 2.0 | % | 2.5 | % |
Page 64
Matrix of Financial Indicators
Pretax Margin
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 9.9 | % | 13.4 | % | 0.3 | % | 6.5 | % | 4.36 | % | 5.4 | % | ||||||||||||
HCA | 10.1 | % | 12.6 | % | 2.1 | % | 5.8 | % | 7.4 | % | 4.4 | % | ||||||||||||
UHS | 5.7 | % | 6.7 | % | 7.3 | % | 6.6 | % | 6.0 | % | 6.5 | % | ||||||||||||
HMA | 19.6 | % | 19.4 | % | 19.9 | % | 19.8 | % | 18.2 | % | 17.1 | % | ||||||||||||
QHGI | 11.2 | % | 10.6 | % | 9.9 | % | 10.7 | % | 4.38 | % | 5.4 | % | ||||||||||||
Competitor Average | 11.7 | % | 12.3 | % | 9.8 | % | 10.7 | % | 9.0 | % | 8.4 | % |
EBITDA / Share Growth
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 6.6 | % | 48.9 | % | -4.4 | % | 17.8 | % | 1.5 | % | 3.5 | % | ||||||||||||
HCA | 29.6 | % | 15.0 | % | -32.4 | % | 3.7 | % | 10.7 | % | 13.1 | % | ||||||||||||
UHS | 23.6 | % | 36.8 | % | 10.8 | % | 30.8 | % | 3.3 | % | 12.5 | % | ||||||||||||
HMA | 23.2 | % | 29.2 | % | 26.6 | % | 25.1 | % | 15.1 | % | 24.7 | % | ||||||||||||
QHGI | 3.5 | % | 31.7 | % | 23.1 | % | 16.5 | % | -14.3 | % | 15.1 | % | ||||||||||||
Competitor Average | 20.0 | % | 28.2 | % | 7.0 | % | 19.0 | % | 3.7 | % | 16.4 | % |
Cash Flow Operations : Revenue
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | -0.2 | % | 3.5 | % | 4.6 | % | 4.1 | % | 5.3 | % | 7.6 | % | ||||||||||||
HCA | 12.7 | % | 13.2 | % | 7.9 | % | 10.3 | % | 7.3 | % | 11.0 | % | ||||||||||||
UHS | 9.9 | % | 12.2 | % | 11.0 | % | 7.6 | % | 8.6 | % | 9.4 | % | ||||||||||||
HMA | 14.0 | % | 13.2 | % | 14.8 | % | 11.2 | % | 12.4 | % | 10.3 | % | ||||||||||||
QHGI | 10.4 | % | 10.4 | % | 11.8 | % | 7.9 | % | 7.8 | % | 9.3 | % | ||||||||||||
Competitor Average | 11.7 | % | 12.3 | % | 11.4 | % | 9.2 | % | 9.0 | % | 10.0 | % |
Page 65
Matrix of Financial Indicators
Cash Flow Operations Cap Ex : Revenue
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | -8.2 | % | -3.1 | % | 0.0 | % | -1.3 | % | -0.1 | % | 2.2 | % | ||||||||||||
HCA | 4.1 | % | 6.1 | % | 0.3 | % | 3.5 | % | -0.4 | % | 4.9 | % | ||||||||||||
UHS | 3.3 | % | 3.3 | % | 1.0 | % | 2.5 | % | 5.3 | % | 3.3 | % | ||||||||||||
HMA | 9.7 | % | 7.5 | % | 8.2 | % | 6.4 | % | 0.7 | % | 3.4 | % | ||||||||||||
QHGI | 3.5 | % | 4.7 | % | 6.8 | % | -0.4 | % | 0.3 | % | 3.4 | % | ||||||||||||
Competitor Average | 5.2 | % | 5.4 | % | 4.1 | % | 3.0 | % | 1.5 | % | 3.7 | % |
Net A/R DSO
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 62.2 | 55.0 | 56.5 | 64.3 | 77.8 | 80.1 | ||||||||||||||||||
HCA | 55.0 | 55.4 | 48.9 | 41.0 | 41.0 | 42.8 | ||||||||||||||||||
UHS | 44.8 | 44.6 | 45.6 | 49.9 | 54.9 | 57.9 | ||||||||||||||||||
HMA | 47.3 | 52.7 | 48.6 | 70.2 | 84.0 | 77.2 | ||||||||||||||||||
QHGI | 62.2 | 61.7 | 64.2 | 63.5 | 73.4 | 69.9 | ||||||||||||||||||
Competitor Average | 52.3 | 53.6 | 51.8 | 56.1 | 63.3 | 61.9 |
Change in A/R DSO
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 14.8 | (7.1 | ) | 1.5 | 7.7 | 13.5 | 2.4 | |||||||||||||||||
HCA | (2.3 | ) | 0.5 | (6.5 | ) | (8.0 | ) | 0.1 | 1.8 | |||||||||||||||
UHS | 5.2 | (0.2 | ) | 1.0 | 4.3 | 5.0 | 2.9 | |||||||||||||||||
HMA | 1.2 | 5.3 | (4.0 | ) | 21.6 | 13.8 | (6.8 | ) | ||||||||||||||||
QHGI | 1.0 | (0.4 | ) | 2.5 | (0.7 | ) | 9.9 | (3.5 | ) | |||||||||||||||
Competitor Average | 1.3 | 1.3 | (1.8 | ) | 4.3 | 7.2 | (1.4 | ) |
Page 66
Matrix of Financial Indicators
Three Year Change in A/R DSO
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 9.2 | 2.1 | 22.7 | 23.6 | ||||||||||||||||||||
HCA | (8.4 | ) | (14.0 | ) | (14.4 | ) | (6.1 | ) | ||||||||||||||||
UHS | 6.0 | 5.2 | 10.3 | 12.3 | ||||||||||||||||||||
HMA | 2.5 | 22.9 | 31.3 | 28.5 | ||||||||||||||||||||
QHGI | 3.1 | 1.3 | 11.7 | 5.7 | ||||||||||||||||||||
Competitor Average | 0.8 | 3.8 | 9.7 | 10.1 |
Revenue : Employee
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 82.8 | 84.7 | 86.4 | 107.7 | ||||||||||||||||||||
HCA | 63.8 | 71.9 | 99.1 | 100.0 | ||||||||||||||||||||
UHS | 81.0 | 97.6 | 105.5 | 106.5 | ||||||||||||||||||||
HMA | 89.5 | 75.9 | 84.7 | 90.0 | ||||||||||||||||||||
QHGI | 78.8 | 83.2 | 79.1 | 84.1 | ||||||||||||||||||||
Competitor Average | 78.3 | 82.2 | 92.1 | 95.2 |
EBITDA : Employee
1995 | 1996 | 1997 | 1998 | 1999 | 2000E | |||||||||||||||||||
THC | 14.5 | 15.5 | 14.8 | 18.3 | ||||||||||||||||||||
HCA | 9.7 | 11.0 | 17.2 | 19.1 | ||||||||||||||||||||
UHS | 11.6 | 13.8 | 13.7 | 14.2 | ||||||||||||||||||||
HMA | 21.9 | 18.7 | 19.8 | 21.2 | ||||||||||||||||||||
QHGI | 14.5 | 15.8 | 12.1 | 13.5 | ||||||||||||||||||||
Competitor Average | 14.4 | 14.8 | 15.7 | 17.0 |
Page 67
[Letterhead of M. Lee Pearce, M.D.]
July 14, 2000
BY OVERNIGHT COURIER
Mr. Jeffrey C. Barbakow
Chairman and Chief Executive Officer
Tenet Healthcare Corporation
3820 State Street
Santa Barbara, CA 93105
Re: Tenet Healthcare Corp. (the Company)
Dear Mr. Barbakow:
As the beneficial owner of 250,042 shares of Tenet Healthcare, I am very concerned about the future of the shareholders investment in Tenet and your role, as a Director, in protecting the investment of all Tenet shareholders. You are undoubtedly aware that, by letter dated July 5, 2000, I nominated an alternate slate of candidates for election to the Companys Board of Directors at this years annual meeting of stockholders. A copy of the nomination letter is attached.
Before we begin to communicate our views to other shareholders, and in no event later than July 24, 2000, I propose a meeting with members of the Board to discuss the possibility of instituting significant changes to improve the Companys operations and maximize value for all shareholders.
The initial concerns that prompted my nominations to the Board fall into three general categories:
(1) the Companys precarious and inadequately disclosed financial position;
(2) Tenets bloated corporate staff and its exorbitant executive compensation; and
(3) the directors disregard for shareholder interests.
We believe the outcome of this years Board elections will turn on these issues unless the current directors and senior management take definitive steps to address them before the next shareholders meeting.
Appalling Financial Performance
Our foremost concern is the Companys precarious and inadequately disclosed economic condition. Under your stewardship, Tenets financial performance has been and continues to be substantially worse than its peers by almost every measure. In many respects, the Company is the industrys worst performer and is in economic distress. In particular:
| Tenet had the worst return on assets in fiscal years ended May 31, 1997, 1999, and is on track to repeat this feat in fiscal 2000. | |
| Tenets 1999 return on equity was the industrys lowest. | |
| Tenets profit margins for earnings before interest, taxes, depreciation and amortization (EBITDA) have declined every year since peaking at 19.8% in fiscal 1996. | |
| Tenets leverage is the highest in the industry. From fiscal 1995 through fiscal 2000 (estimated), Tenet has maintained the industrys highest level of debt to equity. Tenet did so even though Mr. Barbakow announced plans, in 1995, to reduce the debt to equity ratio to 1 to 1 without selling assets. (WSJ, 3/1/95). In fiscal 1999 the Company reported debt of 1.66x equity, compared to 1.15x equity for the industrys largest company, HCA. | |
| For the same period (1995 to 2000 (estimated)), Tenet has also had the highest level of debt to EBITDA. After reaching a low of 2.96x EBITDA in fiscal 1996, this ratio has risen steadily under Mr. Barbakows management to 3.46x EBITDA in fiscal 1999. We estimate the total debt/EBITDA for fiscal 2000 will once again be the industrys highest, even after the Company sold 17 hospitals. | |
| As a result of Tenets heavy leverage, interest coverage (EBITDA/interest) is the industrys lowest. Tenet covered interest by just 3.8x EBITDA in fiscal 1999, compared to 4.7x for Quorum, over 6x for HCA, nearly 10x for Universal Health and 43x for Health Management Associates. | |
| Tenets long-term debt is not investment grade and the average cost of its long-term debt is the industrys highest. Since fiscal 1997, the fourth year of Mr. Barbakows reign, Tenets cost of its long term debt has been the industrys highest. In fiscal 1999, Tenet has paid an average of 7.90% on its debt, compared to 7.14% for HCA and 6.36% for Universal Health. Tenets cost of debt was 0.76% higher than HCAs. That difference cost Tenet approximately $47 million more in interest cost in 1999. | |
| Since fiscal 1994, Tenet has written off more than $2.04 billion after tax, an amount exceeding the total equity turned over to the current management team in 1993. | |
| Cash flow from operations for Tenet is the lowest in the industry as a percent of revenue. After capital expenditures, Tenet produces almost no free cash. Tenet, unfortunately, has not generated any free cash flow over the last four years . . . . (Wall Street |
Transcript, 7/3/2000). In fiscal 1998 and 1999, the Company actually had negative cash flow after capital expenditures. Tenet produces less free cash than any of its peers. | ||
| Part of the reason for the lack of cash generation is poor accounts receivable management. Over the past three-plus years (fiscal 1997-Q3 of 2000), Tenet has seen its accounts receivable days increase by 25.5 days. For a company with $11.4 billion in revenue, 25.5 days equate to a cash need of about $800 million. At Tenets average borrowing cost of 7.9%, this increase costs shareholders roughly $38 million after tax, or $0.12 per share in annual earnings. | |
| Given Tenets appalling financial performance, how will our Company deal with its contingent liabilities? We believe that the Company has significant potential legal liabilities requiring it to spend $60 million annually on 700 outside law firms in addition to some 28 internal lawyers. (House Counsel, Code Blue, GC Christi Sulzbach Applies ER Techniques to Help Revive Tenet Healthcare, May/June 2000). | |
| Among the hundreds of cases pending against the Company, is United States ex rel Scott v. Tenet, et al., in which the relator, a former federal prosecutor, is seeking $150 million for allegedly defrauding Medicare, creating false mortality studies, and falsifying death certificates. | |
| Tenet is the subject of other investigations. HHS/OIG investigations into compensation paid for physician practices appear to be ongoing in multiple jurisdictions. What is the status of these investigations? Is it because of the pendency of governmental investigations that Tenet has been so slow to unwind the physician contracts that are causing the company to lose approximately $100 million per year? What other material litigation and investigations threaten our company? What reserves has Tenet created to address these contingencies? |
Before taking our concerns to other shareholders, we would like to meet with the Tenet Board to set forth our concerns in greater detail and enter into a dialogue with the Board concerning the significant changes needed to address the dire economic issues facing Tenet.
Exorbitant Executive Compensation and Bloated Management
Given the Companys poor performance, we are greatly concerned about the exorbitant executive compensation at Tenet. Mr. Barbakows 1999 compensation was $22.5 million. (L.A. Times, 7/5/2000). In contrast, HCAs CEO elected to serve for the cost of benefits only. Quorums and Health Management Associates chief executives receive just a fraction of the amount paid to Mr. Barbakow. When Aetna terminated Richard Huber, Aetna under his leadership had not performed as badly as Tenet has performed under Mr. Barbakows management. (WSJ, 4/6/2000).
In considering Mr. Barbakows compensation, Tenet shareholders must also take into account the financial and business costs of maintaining Tenets headquarters in Santa Barbara, an affluent coastal enclave where Mr. Barbakow and other senior managers reside. That decision not only necessitates that Tenet maintain an expensive and otherwise unnecessary private air force but also isolates senior management from Tenets real operations and contributes to the appalling financial performance recited above.
The Company has a bloated management structure, in part no doubt because of its absentee senior management. Tenet employs 11 management/support personnel per hospital, about 57% more than HCA which employs only 7 management/support personnel per hospital. Tenet also employs 968 people per hospital, about 19% more than the 812 persons per hospital employed by HCA. Other hospital companies have placed their headquarters in Midwestern cities where tested and experienced hospital company managers are more readily available and where hands-on oversight of hospital properties is feasible and far less expensive.
The Board should have concrete plans for addressing these indefensibly high expenses. At our meeting, we would like to discuss an across-the-board reduction in executive compensation, financial incentives to promote better management, such as tying executive compensation to the Companys real economic performance, relocation of the corporate headquarters, reduction of excessive corporate staff, and other cost containment initiatives.
Disregard for Shareholder Interests
Another critical issue is the directors and managements apparent disregard for shareholder interests. At the last two annual shareholders meetings, the shareholders overwhelmingly voted to recommend that the Board eliminate the staggered system of electing directors. Yet the Board has, twice, defiantly refused to follow the shareholders directive to take action to declassify itself. How can the directors who own less than 0.5% of the Companys outstanding common stock defy the wishes of the vast majority of Tenets shareholders? Compounding the problem is the fact that the Company is still incorporated in Nevada, where shareholder rights are minimal, and that supermajority voting requirements entrench Board incumbents and make change difficult. Research suggests that companies with good corporate governance are more attractive to investors and that companies incorporated in Delaware enjoy enhanced value. (WSJ, 2/28/2000 and 6/19/2000).
Our meeting must therefore include discussion of amending the Charter and By-Laws to eliminate the staggered Board and reincorporating the Company in Delaware, where shareholders have reasonable rights.
Fundamental changes in the way the Company conducts business are long overdue. Tenet is the nations second largest acute care hospital company, with 112 hospitals and annual revenue in excess of $11 billion. Yet despite this strong market position, and the longest bull market in American history, Tenet shareholders who purchased shares in Tenets April 17, 1997 secondary offering at $26.50 per share have seen only a miniscule appreciation (32¢ per share as of the close on July 13, 2000) in their investment in three years.
There is enormous hidden value in Tenet. The concerns outlined above, while of the critical importance, are by no means exhaustive. We believe that our concerns are and will be shared by most other Tenet shareholders, and we will act for their collective benefit. Under no circumstances are we interested in, nor will we accept, any compensation not offered equally to all other shareholders. We look forward to meeting with you by July 24, 2000 to discuss these shareholder issues and our proposals for addressing them. Please advise us no later than 3pm EDT on July 20 whether and where you will meet with us.
Since I am currently traveling, please advise my counsel, Robert B. McCaw of Wilmer, Cutler & Pickering whether and when we can meet. He may be reached by telephone at (212) 230-8810 or fax at (212) 230-8888.
Very truly yours, |
M. Lee Pearce, M.D. |
cc: All Directors
[Letterhead of M. Lee Pearce, M.D.]
August 1, 2000
By Facsimile and Federal Express
Mr. Maurice J. DeWald
Board of Directors
Tenet Healthcare Corporation
3820 State Street
Santa Barbara, CA 93105
Dear Mr. DeWald:
Thank you for coming to Miami to meet with me, Michael Gallagher and Gary Cripe. At that meeting we set forth our view that the Board of Tenet Healthcare Corporation should immediately take the following steps:
| Engage in a comprehensive program to improve cash flow; | |
| Reduce debt and take appropriate steps to improve the Companys debt to investment grade; | |
| Reorganize the Company into a flat, customer responsive, efficient structure; | |
| Reevaluate the Santa Barbara headquarters location and the need for a fleet of private aircraft; | |
| Reincorporate in Delaware; | |
| Eliminate the staggered system for electing directors; | |
| Expand the Board to 15 directors and add our slate of 4 directors to the Board; | |
| Appoint a non-executive chairman; | |
| With the exception of the CEO, remove management, past and present, from the Board; and | |
| Have fraud & abuse compliance report directly to Audit Committee. |
We also renewed our request to meet with the full Tenet Board.
We look forward to your response.
Sincerely
M. Lee Pearce, M.D
cc: All Directors
David L. Dennis
Christi R. Sulzbach, Esq.
[Letterhead of M. Lee Pearce, M.D.]
August 4, 2000
VIA FEDERAL EXPRESS
Mr. Jeffrey C. Barbakow
Chairman and Chief Executive Officer
Tenet Healthcare Corporation
3820 State Street
Santa Barbara, CA 93105
Re: Tenet Healthcare Corporation (the Company)
Dear Mr. Barbakow:
At the July 31, 2000 meeting with Maurice DeWald, David Dennis, and Christi Sulzbach we requested an explanation as to why the Company has failed to comply with the federal securities law obligation to report separately on each segment of its business qualifying as an identifiable operating segment. We referred in particular to Tenets disastrous investment in physician practices. This letter explains the reasons for that request and describes why the shareholders are legally entitled to such operating segment disclosure of the Companys physician practice business.
Under Item 101(b) of Securities Act Regulation S-K and Statement of Financial Accounting Standards (SFAS) No. 131, public companies must disclose separate financial and descriptive information about their reportable operating segments. Separate disclosure is required when a component of an entity:
(a) engages in business activities from which it may earn revenues and incur expenses;
(b) has operating results that are regularly reviewed by the enterprises chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance; and
(c) has discrete information available about it. From a quantitative standpoint, if an operating segments reported revenue, absolute reported profit or loss, or assets equal 10 percent or more of the combined entity, the enterprise must report the information required by SFAS No. 131 separately.
In its filings with the SEC, Tenet has maintained that the Companys provision of health care through its domestic general hospitals, physician practices, and related health care facilities comprises a single reportable operating segment under [SFAS No. 131]. (Form 10-
K, filed Aug. 26, 1999.) That position, however, is contradicted by the Companys own public filings, which reveal that the physician practice business:
(a) engages in revenue-producing activities;
(b) is reviewed regularly by management; and
(c) is supported by discrete financial information all of which indicate that Tenets physician practices should be reported as a separate operating segment.
First, the Companys filings make it unequivocally clear that management thinks of its physician practice operations as a separate business. Tenets filings are replete with descriptions of the physician practices as a business. (See, e.g., Rule 424(b)(3) Prospectus to Registration on Form S-4, filed May 4, 2000; Form 10-K, filed Aug. 26, 1999; Form 10-K, filed Apr. 28, 1999; Form S-4, filed Apr. 23, 1999.)
Second, the Companys 1999 annual report makes clear that the physician practice operations produce substantial revenue. From 1997 to 1999, according to the report, Tenets increases in net operating revenues from other operations were primarily the result of new physician practices acquired as part of hospital acquisitions. (Form 10-K, filed Aug. 26, 1999.)
Third, the physician practice business is regularly reviewed by Tenets top management. The 1999 annual report gives a detailed description of managements involvement with and plans for the physician practices:
The Company is in the process of reevaluating its physician strategy in every one of its markets and is developing plans to allow a significant number of its existing contracts to expire. Such plans could result in a decision to exit the physician practice business during fiscal 2000. The Company would expect to incur significant charges on the disposal of this business, including estimated operating losses during the phase out period, if it decides to exit the business entirely. . . . Such charges may require significant cash expenditures as contract settlements with physicians and physician groups are made. The benefits of such a strategy, which could be significant, would not be expected to occur until fiscal 2001 and beyond. |
(Id.) Managements belief that the Companys physician practice business could be readily separated from its other businesses lends further support to the notion that the physician practice business should be reported as a separate operating segment.
Fourth, the Companys physician practice business is supported by discrete financial information. In two recent disclosures, the Company stated that the physician practice
business has not been profitable. (Id.; Form 10-Q, filed Apr. 13, 2000.) Although those disclosures fail to identify the extent of the losses suffered, they confirm information revealed by Tenet executives in recent investor presentations that the Company has lost $100 million per year on the physician practices certainly a material amount.
The impairment charges and write-offs taken by the Company since fiscal 1997 also support both the existence of discrete information and the materiality of information about the physician practice business. In particular:
| The Company recorded $177 million (Form 10-Q, filed Apr. 13, 2000) of impairment and unusual charges in fiscal 2000 relating to its decision to terminate physician employment and management agreements as part of its strategy to reduce losses from its physician practice operations. (Press Release, March 31, 2000.) | |
| Tenet took charges of $38 million (equivalent to 8% of its pre-tax income of $474 million) in fiscal 1999 for the impairment of property, equipment and goodwill at 20 physician practices and other ancillary health care businesses. (Form 10-K, filed Aug. 26, 1999.) | |
| In fiscal 1998, the Company wrote off $41 million in goodwill and other assets relating to its physician practices (equivalent to 6% of the Companys pre-tax income of $647 million). (Id.) | |
| In fiscal 1997, Tenet wrote off $60 million in goodwill and other long-lived assets of physician practices not deemed to be fully recoverable, and $18 million for a restructuring of physician practices, including severance for the physicians, write-offs of computer equipment and software, physician contract terminations and the costs to reorganize regional management service organizations. (Id.) The 1997 charges totaled $78 million, an amount exceeding the Companys pre-tax profits for that year. |
Given the magnitude of the above charges and write-offs, there is reason to question managements position that the net operating revenues and operating losses from [the physician practice business] activities have not been material. (Form 10-Q, filed Apr. 14, 2000.)
The SECs Division of Corporation Finance recently underscored the importance of segment reporting in its June 30, 2000 publication of Current Accounting and Disclosure Issues, stating, [i]f the chief operating decision maker [of a company] receives reports of a components operating results on a quarterly or more frequent basis, the staff may challenge [the companys] determination that the component is not a segment for purposes of SFAS 131 . . . . The purpose of segment reporting is to increase investor awareness and knowledge by giving investors access to substantially the same information used by a companys chief operating decision makers to evaluate segment performance and resource allocation.
By failing to report on its physician practice business as a separate operating segment, Tenets management has frustrated that purpose and has interfered with the ability of shareholders to evaluate their exposure from that component of the Companys operations. The Company has kept the market and shareholders in the dark about the value and wisdom of Tenets strategy of investing in physician practices.
Managements disregard of segment reporting requirements also raises concerns about regulatory liability. Under similar circumstances, the SEC sanctioned Sony for filing disclosures that improperly treated its music and motion picture businesses as a single operating segment. See In the Matter of Sony Corporation, Exchange Act Release No. 34-40305, 67 SEC Docket 1609-25 (Aug. 5, 1998). The SEC found that consolidated treatment of such distinct industry segments misleadingly obscured the nature and extent of the losses sustained by Sonys motion picture unit, and imposed a $1 million civil penalty on Sony for violating Section 13(a) of the Exchange Act. See id.; SEC v. Sony Corp., Civ. A. No. 1:98CV1935, Settled Complaint (D.D.C. Aug. 5, 1998).
Finally, we were troubled by the Companys response when we inquired about segment reporting at our July 31 meeting. The response compared the physician practice business to the hospital custodians; we were told that the physician practice business was no more a separate segment than were the custodians. We believe the comment is indicative of a negative attitude toward physicians that is the cause of many of Tenets difficult relationships with physicians that have adversely affected the Companys business performance and the quality of patient care.
Tenet is scheduled to file its Form 10-K for the fiscal year ending May 31, 2000 this month. Before the directors accept personal responsibility by signing the form, we believe they should require management to provide segment reporting for all components of Tenet that satisfy SFAS No. 131. This applies in particular to the physician practice business for fiscal 2000 and earlier periods.
Very truly yours,
M. Lee Pearce, M.D
cc: All Directors
David L. Dennis
Christi R. Sulzbach
(all by Federal Express)
|